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A B S T R A C T
Background
Depression is common in the postnatal period and can lead to adverse effects on the infant and wider family, in addition to the
morbidity for the mother. It is not clear whether antidepressants are effective for the prevention of postnatal depression and little is
known about possible adverse effects for the mother and infant, particularly during breastfeeding. This is an update of a Cochrane
Review last published in 2005.
Objectives
To assess the effectiveness of antidepressant medication for the prevention of postnatal depression, in comparison with any other
treatment, placebo or standard care.
Search methods
We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR both Studies and References),
CENTRAL (Wiley), MEDLINE (OVID), Embase (OVID), PsycINFO (OVID), on 13 February 2018. We also searched the World
Health Organization (WHO) trials portal (ICTRP) and ClinicalTrials.gov on 13 February 2018 to identify any additional unpublished
or ongoing studies.
Selection criteria
Randomised controlled trials (RCTs) of initiation of antidepressants (alone or in combination with another treatment), compared with
any other treatment, placebo or standard care for the prevention of postnatal depression among women who were either pregnant or
had given birth in the previous six weeks and were not currently depressed at baseline.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. We requested missing information from investigators wherever
possible and sought data to allow intention-to-treat analyses.
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Main results
Two trials including a total of 81 participants fulfilled the inclusion criteria for this review. All participants in both studies had a history
of postnatal depression and were not taking antidepressant medication at baseline. Both trials were conducted by the same research
group. Risk of bias was low or unclear in most domains for both studies. We were unable to perform a meta-analysis due to the small
number of studies.
One study compared nortriptyline with placebo and did not find any evidence that nortriptyline was effective in preventing postnatal
depression. In this study, 23% (6/26) of women who took nortriptyline and 24% (6/25) of women who took placebo experienced
postnatal depression (RR 0.96, 95% CI 0.36 to 2.59, very low quality evidence) in the first 17 weeks postpartum. One woman taking
nortriptyline developed mania; and one side effect, constipation, was more common among women taking nortriptyline than those
taking placebo.
The second study compared sertraline with placebo. In this study, 7% (1/14) of women who took sertraline developed postnatal
depression in the first 17 weeks postpartum compared with 50% (4/8) of women who took placebo. It is uncertain whether sertraline
reduces the risk of postnatal depression (RR 0.14, 95% CI 0.02 to 1.07, very low quality evidence). One woman taking sertraline had
a hypomanic episode. Two side effects (dizziness and drowsiness) were more common among women taking sertraline than women
taking placebo.
Conclusions are limited by the small number of studies, small sample sizes and incomplete outcome data due to study drop-out which
may have led to bias in the results. We have assessed the certainty of the evidence as very low, based on the GRADE system. No
data were available on secondary outcomes of interest including child development, the mother infant relationship, breastfeeding,
maternal daily functioning, family relationships or maternal satisfaction.
Authors’ conclusions
Due to the limitations of the current evidence base, such as the low statistical power of the included studies, it is not possible to
draw any clear conclusions about the effectiveness of antidepressants for the prevention of postnatal depression. It is striking that no
new eligible trials have been completed in the period of over a decade since the last published version of this review. Larger trials
are needed which include comparisons of antidepressant drugs with other prophylactic treatments (e.g. psychological interventions),
and examine adverse effects for the fetus or infant. Future reviews in this area may benefit from broadening their focus to examine
the effectiveness of antidepressants for the prevention of perinatal (i.e. antenatal or postnatal) depression, which could include studies
comparing antidepressant discontinuation with continuation for the prevention of relapse of depression during pregnancy and the
postnatal period.
P L A I N L A N G U A G E S U M M A R Y
Antidepressant medication for preventing postnatal depression
Review question
We examined the evidence to see whether antidepressants can prevent women from experiencing depression in the postnatal period,
when compared with any other treatment, sham treatment (placebo), or standard clinical care. The studies we identified included only
women who had previously experienced postnatal depression, and had a higher risk of experiencing postnatal depression again.
Background
Postnatal depression is a common condition. Approximately 10 to 15 of every 100 women experience elevated symptoms of depression
in the period after giving birth, and 5 in every 100 women will experience a depressive disorder. Symptoms of depression include low
mood, loss of pleasure, and feelings of guilt or worthlessness. Postnatal depression has an impact on themother, and may have a negative
impact on the well-being of the infant and wider family.
Women with a history of depression - and particularly women who have previously experienced postnatal depression - have a higher
risk of postnatal depression. Pregnant women who are not depressed, but are at high risk of developing postnatal depression, may want
to consider taking measures to try to prevent depression developing in the postnatal period.
We examined whether taking antidepressants during pregnancy or after giving birth can prevent women from developing postnatal
depression.
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Study characteristics
We identified two small, relevant trials. All the women in these trials had a history of postnatal depression, but were not depressed or
using antidepressants at the beginning of the studies. Both studies compared antidepressant medicine with placebo. Women started
taking the medicine or placebo on the first day after giving birth.
In the larger study (56 women), the antidepressant given to women was nortriptyline, which is a tricyclic antidepressant. In the other
study (25 women), the antidepressant used was sertraline which is a selective serotonin reuptake inhibitor (SSRI); these types of
antidepressants work in different ways. The women and the researchers assessing the outcomes in both studies did not know which
women were taking antidepressants and which placebo (i.e. both studies were ’double-blind’). Both studies were funded by the National
Institute of Mental Health (NIMH), a US government organisation.
Key results
There was no evidence that nortriptyline prevented postnatal depression. During the 17-week treatment period, 6 of the 26 women
takingnortriptyline experiencedpostnatal depression comparedwith 6of the 25women takingplacebo.Onewoman taking nortriptyline
developed mania (a state of abnormally high arousal and energy level), and constipation was more common among women taking
nortriptyline, but other unwanted, or harmful, effects did not differ between groups.
In the sertraline study, 1 of the 14 women taking sertraline developed postnatal depression compared with 4 of the 8 women taking
placebo (during the 17-week treatment period). This study was very small, so we can’t be sure whether the difference between sertraline
and placebo is due to chance, or whether sertraline does prevent postnatal depression among women with a history of postnatal
depression. One woman taking sertraline experienced a hypomanic episode (a state like mania but less severe); and dizziness and
drowsiness were more common among women taking sertraline than women taking placebo.
Quality of the evidence
This evidence is current to February 2018.
We could only identify two relevant studies, which had small numbers of participants and inconsistent findings, and were conducted
by the same research group. Therefore we consider the quality of evidence in this review to be very low. Further studies with larger
samples are needed before we can know whether antidepressants can prevent postnatal depression.
It is worth noting that no new relevant trials have been completed in the 10 years since we last examined this evidence. It may be
useful for future medical studies to investigate whether antidepressants can prevent depression during pregnancy as well as during the
postnatal period; and whether women who continue to take antidepressants during pregnancy (compared with stopping medication)
are less likely to have a relapse of depression at this time.
We also need studies which have longer follow-ups periods; examine outcomes and side effects for both the mother and fetus or
breastfeeding infant; and compare antidepressants with other preventative interventions (such as psychological therapies).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Nortripyline for the prevention of postnatal depression
Patient or population: women with a history of postnatal depression
Intervention: nortripyline
Control: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Tricyclic antidepres-
sants
Postnatal depression
(17 weeks)
240 per 10001 230 per 1000
(86 to 622)
RR 0.96
(0.36 to 2.59)
51
(1 study)
⊕©©©
very low2,3
Adverse effects expe-
rienced by mother and/
or foetus or nursing
baby
51
(1 study)
⊕©©©
very low2,3
1 woman assigned to
nortriptyline developed
mania within the f irst
week
Const ipat ion was re-
ported more f requent ly
in the nortriptyline than
placebo group (78%
among women taking
nortriptyline and 22%
among women taking
placebo; Fischer’s ex-
act test P < 0.001)
. This was the only
side ef fect that was
more common among
women taking nortripty-
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l ine than placebo, but
the other side ef fects
assessed and the pro-
port ion of women expe-
riencing these side ef -
fects was not reported
Acceptability of treat-
ment (17 weeks)
51
(1 study)
⊕©©©
very low2,3
Acceptability of treat-
ment was not assessed
direct ly but 1 woman
was lost to follow-up
f rom the nortriptyline
arm (and 1 women in
the nortriptyline arm
withdrew af ter devel-
oping mania in the
f irst postpartum week)
and 3 withdrew f rom
the placebo arm (ow-
ing to side ef fects, per-
sonal reasons and preg-
nancy)
4 part icipants declined
to take the study drug
af ter randomisat ion
Overall maternal satis-
faction (17 weeks)
No data available
Improvement in the
maternal relationship
with the baby (17
weeks)
No data available
Establishment or con-
tinuation of breast-
feeding (17 weeks)
No data available
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Assumed risk calculated as the proport ion of women on placebo with the outcome (postnatal depression) mult iplied by 1000
2Downgraded due to high risk of bias in 1 domain (incomplete outcome data)
3Downgraded twice due to imprecision (only 1 small study available for this comparison)
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B A C K G R O U N D
Description of the condition
Many women experience depression after they give birth, which
is known as postnatal or postpartum depression (O’Hara 1996;
Howard 2014). Depressive episodes are characterised by a variety
of symptoms, such as low mood, loss of enjoyment, feelings of
guilt or worthlessness, loss of energy and possibly suicidal ideation.
Standard diagnostic criteria for depression are used to diagnose de-
pression in the postnatal period (e.g. theDiagnostic and Statistical
Manual ofMentalDisorders (DSM-5) or theTenthRevisionof the
International Classification of Disease (ICD-10) (World Health
Organization 2004; American Psychiatric Association 2013). As
well as the impact on the mother, postnatal depression can have
negative implications for the infant and the wider family (Cox
1982; Stein 2014). These outcomes may include adverse effects
on mother infant attachment, and the emotional or behavioural
development of the child (Stein 2014).
It is estimated that approximately 10% to 15% of women expe-
rience elevated symptoms of depression in the period after giving
birth, and approximately 5% of women have an episode of major
depression at this time (Howard 2014).Women who have had one
or more previous episodes of depression are at increased risk of de-
veloping postnatal depression, and this is particularly the case for
women with a previous episode of postnatal depression (Howard
2014). The period of time in which episodes of depression are
classified as ’postnatal depression’ varies between studies, but often
refers to onset of depression in the first three months (e.g. Yonkers
2008) or six months (e.g. Sharp 2010) after delivery. However,
it is important to remember that many women presenting with
depression in the postnatal period may have developed depres-
sion before delivery, either before conception or during pregnancy
(Wisner 2013).
Description of the intervention
Antidepressants are medications to treat the symptoms of depres-
sion, and meta-analyses have shown that their effectiveness in-
creases with the severity of depression (Fournier 2010). In gen-
eral, medication exposure in pregnancy should beminimisedwhen
possible, and non-pharmacological interventions can be effective
for the prevention and treatment of mild to moderate depression
(Dennis 2007; Morrell 2016). However, antidepressant medica-
tions are clinically indicated for women with more severe mental
disorders during pregnancy or the postnatal period when there
are substantial risks to the mother, the pregnancy, and the fetus
or infant (Howard 2014). Current NICE guidelines recommend
the use of antidepressants for the treatment of moderate to se-
vere depression and also for the prevention of depressive episodes
in those with a high risk of relapse or a history of recurrent de-
pression (NICE 2009). This review investigates the initiation of
antidepressants during pregnancy or the early postpartum period
for the prevention of postnatal depression. Antidepressants can be
classified into the following types.
• Selective serotonin reuptake inhibitors (SSRIs): e.g.
fluoxetine, paroxetine, sertraline, citalopram
• Tricyclic antidepressants (TCAs): e.g. amitriptyline,
nortriptyline, doxepin
• Heterocyclic antidepressants: e.g. mianserin
• Monoamine oxidase inhibitors (MAOIs): e.g. phenelzine,
brofaromine
• Noradrenaline re-uptake inhibitors (NARIs): e.g. reboxetine
• Noradrenaline-dopamine re-uptake inhibitors (NDRIs):
e.g. bupropion
• Serotonin-noradrenaline re-uptake inhibitors (SNRIs): e.g.
venlafaxine, duloxetine
• Noradrenergic and specific serotonergic antidepressants
(NASSAs): e.g. mirtazapine
• Serotonin antagonist and re-uptake inhibitors (SARIs): e.g.
trazodone
• Other unclassified antidepressants: e.g. vilazodone
The fetus and the infant may be affected by exposure to psy-
chotropic drugs across the placenta or through breastfeeding, al-
though exposure to antidepressants in breastfed infants is five to
ten times lower than exposure in utero (Howard 2014). Breast-
feeding women have been advised to avoid doxepin (a TCA) as its
main metabolite has been found in breast milk in higher concen-
trations than other antidepressants (Eberhard-Gran 2006). More
broadly, there are limited data on the safety of antidepressants dur-
ing breastfeeding (particularly for longer-term child outcomes) but
the findings to date suggest that the benefits of taking antidepres-
sants may outweigh the risks in breastfeeding women who need
treatment for depression (Howard 2014). The risk benefit ratio
is less clear for women offered antidepressants as a preventative
intervention in the postpartum period, but it is important to note
that the women who are offered antidepressants as a preventative
intervention at this time often have a history of severe episodes of
postnatal depression and are therefore at higher risk of experienc-
ing another episode of postnatal depression.
How the intervention might work
The function of antidepressants is not fully understood. There is
evidence from studies of both patients and healthy controls that
antidepressants affect activity in areas of themedial prefrontal cor-
tex and limbic system that are associated with emotion processing
(e.g. the anterior cingulate, amygdala and thalamus), leading to
increased activity in response to positive emotions and decreased
activity in response to negative emotions (see systematic review
and meta-analysis by Ma 2014). Most antidepressants appear to
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inhibit uptake of monoamine neurotransmitters (e.g. serotonin
or noradrenaline (norepinephrine)) into neurons, which increases
the concentrations of these neurotransmitters at synapses (Berton
2006). The majority of evidence on the effects of antidepressants
comes from treatment studies, but there is also evidence that an-
tidepressants can reduce the risk of relapse of depression compared
with placebo (Geddes 2003). Women at higher risk of postnatal
depression (such as those with a history of postnatal depression)
may be more likely to benefit from preventative interventions and
also more motivated to accept them. This is particularly relevant
when considering antidepressant prevention of postnatal depres-
sion, given the possible adverse effects of antidepressant use on the
breastfeeding infant (or on the fetus, if started during pregnancy).
Why it is important to do this review
This is an update of a Cochrane Review published in 2005, and
previously assessed as up to date in 2007. Research into postnatal
depression is important due to its high prevalence and potential
negative impact on both the mother and child, as well as other
family members (Cox 1982; Stein 2014). Antidepressants have
been shown to be more effective than placebo in treating postnatal
depression (Molyneaux 2014); but it is also important to consider
the prevention of postnatal depression, particularly for high-risk
women. Other interventions have been found to be effective for
preventing postnatal depression, for example psychological and
psychosocial interventions (Morrell 2016). However, these psy-
chological interventions are not always available and some women
may be recommended antidepressants as a preventative interven-
tion, particularly those with a history of severe postnatal depres-
sion and those who have previously responded well to antidepres-
sants. It is therefore important to determine whether antidepres-
sants are effective for the prevention of postnatal depression. It is
also important to examine antidepressant prevention of postnatal
depression owing to the additional issues around the safety for the
fetus (if preventative interventions begin during pregnancy) or the
breastfeeding infant.
O B J E C T I V E S
To assess the effectiveness of antidepressant medication for the
prevention of postnatal depression, in comparison with any other
treatment, placebo or standard care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised controlled trials
(RCTs), including cluster and cross-over trials.
Types of participants
Participant characteristics
Women who are pregnant or have given birth in the last six weeks,
who are not depressed at the start of the trial.
Diagnosis
Women must not be depressed at the beginning of eligible tri-
als, as the focus of the review is the prevention of depression in
the postnatal period. Trials may include women with a history of
depression or postnatal depression only, or offer the intervention
to all at-risk women during pregnancy or the early postpartum
period.
Co-morbidities
We placed no restrictions on studies involving participants with
co-morbid medical or psychological disease or disorders, provided
the co-morbidities were not the primary focus of the study.
Setting
We placed no restrictions on the setting of the studies.
Types of interventions
Experimental intervention
Any antidepressant medication at any dose, alone or in combina-
tion with another treatment, initiated in at least one arm of a trial.
For the purposes of this review antidepressant medications were
classified as follows.
• Selective serotonin reuptake inhibitors (SSRIs): e.g.
fluoxetine, paroxetine, sertraline, citalopram
• Tricyclic antidepressants (TCAs): e.g. amitriptyline,
nortriptyline, doxepin
• Heterocyclic antidepressants: e.g. mianserin
• Monoamine oxidase inhibitors (MAOIs): e.g. phenelzine,
brofaromine
• Noradrenaline re-uptake inhibitors (NARIs): e.g. reboxetine
• Noradrenaline-dopamine re-uptake inhibitors (NDRIs):
e.g. bupropion
• Serotonin-noradrenaline re-uptake inhibitors (SNRIs): e.g.
venlafaxine, duloxetine
• Noradrenergic and specific serotonergic antidepressants
(NASSAs): e.g. mirtazapine
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• Serotonin antagonist and re-uptake inhibitors (SARIs): e.g.
trazodone
• Other unclassified antidepressants: e.g. vilazodone
Comparator intervention
Placebo, standard clinical care, or any other treatment, such as
psychological interventions (e.g. CBT) or psychosocial interven-
tions (e.g. peer support).
Types of outcome measures
We included studies that meet the above inclusion criteria regard-
less of whether they report on the following outcomes.
Primary outcomes
1. Onset of postnatal depression. Depression was defined as mea-
sured in each trial using any of the following: clinical diagnos-
tic interview; standard observer-rated depression symptom scales
based on a recognised diagnostic scheme (e.g. the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) or the Interna-
tional Classification ofDisease (ICD-10); other standardised crite-
ria (e.g. the Research Diagnostic Criteria (RDC) (Spitzer 1978));
or screening instruments (e.g. the Edinburgh Postnatal Depres-
sion Scale (EPDS) (Cox 1987)). Studies examining onset of de-
pression up to six months postpartum were eligible. Time to onset
was reported if examined in individual studies.
2. Adverse events experienced by themother, or the fetus/breastfed
infant, or both.
Secondary outcomes
3. Acceptability of treatment assessed directly through question-
naires for trial participants or indirectly through drop-out rates.
4. Cognitive and emotional development of the infant (e.g. as-
sessment of the mental and psychomotor development of infants
using the Mental Development Index (MDI) and Psychomotor
Development Index (PDI) of the Bayley Scales of Infant Devel-
opment (Bayley 2006); parental report of child development us-
ing the Parent Report of Children’s Abilities-Revised (PARCA-R)
(Johnson 2008).
5. Overall maternal satisfaction (e.g. self-reported general satisfac-
tion, satisfaction with self/baby/partner using the Mackay Child-
birth SatisfactionRating Scale (Goodman 2004); self-reported be-
liefs, values and perceived skills regarding motherhood using the
Parenting Sense of Competence Scale (Gidaud-Wallston 1978).
6. Improvement in the maternal relationship with the baby (e.g.
improvedmother infant interactionsmeasured using theCARE-
Index (Crittenden 1988).
7. Improvement in the mother’s ability to carry out daily activities
and social functioning (e.g. improved score on the Global Assess-
ment of Functioning Scale (Endicott 1976); increased social net-
work, measured using the Social Network Index (Cohen 1997).
8. The establishment or continuation of breastfeeding (e.g. rates
of establishment, continuation or discontinuation).
9. Prevention of neglect or abuse of the baby (e.g. using the Parent-
Report Multidimensional Neglectful Behavior Scale (Kaufman
Kantor 2004).
10. The effect on marital and family relationships (e.g. using the
Quality of Marriage Index (Norton 1983).
Timing of outcome assessment
• Zero to eight weeks: immediate effects.
• Nine to 16 weeks: short-term effects.
• 17 to 24 weeks: intermediate effects.
• More than 24 weeks: long-term effects.
Hierarchy of outcome measures
If multiple measures had been used for one of these outcomes,
we intended to select measures which have been validated among
womenwith postnatal depression abovemeasures which have been
validated in other populations. If possible, we intended to report
one outcome from each of the above time periods.
Search methods for identification of studies
Cochrane Common Mental Disorders Controlled
Trials Register (CCMDCTR)
The Cochrane Common Mental Disorders Group (CCMD)
maintains two archived clinical trials registers at its editorial base
in York, UK: a references register and a studies-based register. The
CCMDCTR-References Register contains over 40,000 reports of
RCTs in depression, anxiety and neurosis. Approximately 50%
of these references have been tagged to individual, coded trials.
The coded trials are held in the CCMDCTR-Studies Register
and records are linked between the two registers through the use
of unique Study ID tags. Coding of trials is based on the EU-
Psi coding manual, using a controlled vocabulary; (please contact
the CCMD Information Specialists for further details). Reports
of trials for inclusion in the Group’s registers are collated from
routine (weekly), generic searches of MEDLINE (1950 to 2016),
Embase (1974 to 2016) and PsycINFO (1967 to 2016); quarterly
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) and review-specific searches of additional databases.
Reports of trials are also sourced from international trial registers
via theWorldHealthOrganization’s trials portal (the International
Clinical Trials Registry Platform (ICTRP)), pharmaceutical com-
panies, the handsearching of key journals, conference proceedings
and other (non-Cochrane) systematic reviews and meta-analyses.
Details of CCMD’s generic search strategies (used to identify
RCTs) can be found on the Group’s website. The Group’s Spe-
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cialised Register had fallen out of date with the Editorial Group’s
move from Bristol to York in the summer of 2016.
Electronic searches
1. CCMDCTR
We conducted an update search of the CCMDCTR-Studies and
References registers on 13 February 2018 using the terms listed in
Appendix 1.
2. International trial registries
We also searched the WHO trials portal (ICTRP) and Clinical-
Trials.gov on 13 February 2018 to identify any additional unpub-
lished or ongoing studies using the following terms.
ICTRP: depress* and prevent* and postpartum or depress* and pre-
vent* and postnatal
or depress* and prophyla* and postpartum or depress* and prophyla*
and postnatal
CT.gov: (prevention or prevent or prophylaxis) and (depression or
depressive) and (postnatal or post-natal or postpartum or post-partum)
Records were filtered (for pharmacological interventions) using
Excel.
3. Web of Science (citation search)
A cited reference search of the Web of Science was also conducted
(4 May 2016), for reports citing the first version of this review,
a companion publication published in PLOS Medicine (Howard
2006) and all of the included studies to date.
Earlier searches conducted for the first version of this review (to
June 2007) can be found in Appendix 2.
4. In keeping with MECIR conduct standard c37, a final pre-
publication search was conducted on 13 February 2018 on the
following databases (2016 to date).
• Cochrane Common Mental Disorders Specialised Register;
• Ovid MEDLINE;
• Ovid Embase;
• Ovid PsycINFO;
• CENTRAL;
• Trial Registries.
This was necessary as the Group’s Specialised Register had fallen
out of date with the Editorial Group’s move from Bristol to York
in the summer of 2016. The details of this search can be found in
Appendix 3
Searching other resources
Grey literature
We did not search grey literature for this update of the review as
relevant unpublished studies should be identified through searches
of clinical trials registries.
Reference lists
Wechecked reference lists and conducted forward citation tracking
for all included studies to identify additional studies missed from
the original electronic searches (for example unpublished or in-
press citations).
Correspondence
We contacted trialists for information on unpublished or ongoing
studies, or to request additional trial data when required.
Data collection and analysis
Selection of studies
Titles and abstracts of studies identified in the above search were
examined by two review authors (LT and EM) independently. We
removed duplicate records; and obtained the full-text article for
any publication which was potentially relevant. LT and EM then
independently assessed full-text articles to examine whether they
fulfilled the inclusion criteria. Where the authors disagreed, the
matter was discussed until agreement was reached; or we sought
guidance and arbitration from a third review author (LH) when
necessary.
We collated multiple reports related to the same study so that data
from each trial were included only once even if the trial, or aspects
of it, had been reported in multiple published papers. When mul-
tiple reports of a single trial were identified, we included the report
with the largest sample size. We recorded the selection process in
detail and produced a PRISMA flow diagram and ‘Characteristics
of excluded studies’ table.
Data extraction and management
Two review authors (LT and EM) independently extracted data
from the trial reports. We developed a data extraction form and
piloted it for this review. We requested missing information from
investigators wherever possible; and we extracted the following
study characteristics.
1. Methods: study design, study setting, number and location
of study centres, study date and duration, details of blinding/
allocation concealment.
2. Participants: total number of participants and number in
each group, inclusion and exclusion criteria, key socio-
demographic information (e.g. age), number of withdrawals.
3. Interventions: number of intervention groups, type of
interventions and comparisons, duration of intervention and key
details (e.g. dosage), details of any ’run-in’ period.
4. Outcomes: primary and secondary outcomes specified and
reported, time points reported, adverse events, and details of
measures used to assess outcomes.
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5. Analysis: statistical techniques used, subgroup analyses,
number of participants included in each analysis, study results.
6. Notes: trial funding and conflicts of interest of trial authors.
Where possible, we resolved any inconsistencies in the information
extracted by discussion between review authors (LT and EM).
When this was not possible, we sought further information from
the trial investigator(s).One author (EM) entered data intoReview
Manager 5 software (RevMan 5); and all entries were checked by
the other author (LT). We double-checked that data were entered
correctly by comparing the data presented in the systematic review
with the study reports. LT spot-checked study characteristics for
accuracy against the trial report.
Main comparisons
Themain planned comparisonwas antidepressantmedication ver-
sus placebo. We had also planned to compare antidepressants with
standard clinical care and with psychological or psychosocial in-
terventions but no included studies provided data for these com-
parisons. Comparisons are presented separately for individual an-
tidepressants.
Assessment of risk of bias in included studies
Two review authors (LT and EM) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion, including a third
review author (LH) when necessary. We assessed risk of bias in the
following domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other bias (adherence to medication)
We judged each potential source of bias as high, low or unclear and
provided a supporting quotation from the study report together
with a justification for our judgment in the ’Risk of bias’ table.We
considered blinding separately for different key outcomes where
necessary. We assessed selective outcome reporting by obtaining
trial protocols (where possible) and comparing these with the final
trial report. Where information on risk of bias relates to unpub-
lished data or correspondence with a trialist, we noted this in the
’Risk of bias’ table.
Measures of treatment effect
We presented the primary outcome (postnatal depression) using
risk ratios (RR) for all studies. If the RR was not presented in
the original trial report, we calculated it for this review. We sum-
marised other outcomes using the data as quoted in the original
papers (e.g. odds ratio (OR), hazard ratio (HR), RR, mean dif-
ference (MD)). If there had been sufficient data for meta-analyses
to be performed on any outcomes (i.e. three or more compara-
ble studies), we would have calculated the RR for dichotomous
outcomes, the HR for time-to-event outcomes, and the MD or
standardised mean difference (SMD) for continuous outcomes.
Dichotomous data
We calculated the RR and its 95% confidence interval (CI) for
dichotomous outcome data. It has been shown that RRs are more
intuitive than ORs and that ORs tend to be interpreted as RRs
by clinicians (Bland 2000). This misinterpretation then leads to
an overestimation of the effect. If necessary for studies included in
future updates of this review, we will attempt to convert contin-
uous primary outcome measures to dichotomous data using cut-
off points on rating scales to identify those who did and did not
fulfil the criteria for depression.
Time-to-event data
Wepresented theHRand95%CI for time-to-event outcomedata,
when applicable. In future updates of this review, if time-to-event
data is given in an original paper but not presented as an HR then
the HR will be estimated using the methods described by Tierney
2007. If there are sufficient studies presenting time-to-event data
to conduct a meta-analysis in future updates of this review, we will
pool data following the guidance given in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
Continuous data
We did not conduct any meta-analyses for this review. However, if
a meta-analysis of continuous data is performed in future updates
of the review, we will calculate themean difference between groups
(if studies used the same outcome measure) or the standardised
mean difference (if studies used different measures to assess the
same outcome). If future updates of this review include reports
which present standard errors instead of standard deviations, we
will convert these to standard deviations. If standard deviations are
not reported and cannot be calculated from the available data, we
will request the necessary data from trial authors. In the absence of
data from authors, we will use the mean standard deviation from
other comparable studies.
Unit of analysis issues
Cluster-randomised trials
Cluster RCTs must be analysed taking into account the clustered
nature of the data. No cluster RCTs meeting inclusion criteria for
this review were identified, but we will use the following methods
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to address any cluster RCTs included in future updates of this re-
view: we will extract the intra-cluster correlation coefficient (ICC)
for each trial or request it from study authors if not reported. If
the ICC cannot be obtained, estimates of the ICC from similar
studies will be used to ’correct’ for clustering, in line with guidance
from theCochraneHandbook for Systematic Reviews of Interventions
(Higgins 2011). The generic inverse variance method will be used
to meta-analyse results from cluster RCTs (Higgins 2011).
Cross-over trials
The results of cross-over trials may be influenced by the carry-over
effect, whereby a treatment in the first randomised treatment pe-
riod of the trial has an effect which carries over to the second ran-
domised treatment period. Cross-over trials are also not appropri-
ate if the condition of interest is unstable (Elbourne 2002). Both
of these issues apply to trials of postnatal depression prevention.
We identified no cross-over trials for inclusion in this review, but
if we identify any in future updates of the review we will include
only data from the first randomised treatment period.
Studies with multiple treatment groups
Trials with more than two relevant treatment groups can lead to
issues with pairwise meta-analysis. We identified no studies with
more than two groups for inclusion in this review but if we identify
any in future updates the following methods will be used, in line
with theCochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). For dichotomous outcomes, we will combine the
active treatment groups into a single arm for comparison against
the control group; or we will split the control group equally for
separate comparisons with the active treatment groups (based on
sample size). For continuous outcomes, we will pool the means
and standard deviation in each treatment group (as a function of
the number of participants in each group) for comparison with
the control group.
Dealing with missing data
We contacted study investigators to verify key study character-
istics and obtain missing numerical outcome data where neces-
sary. When possible, we presented data on a ’once randomised, al-
ways analyse’ basis, assuming an intention-to-treat (ITT) analysis.
When studies had not performed ITT analyses, we calculated the
RR based on ITT assuming a negative outcome (i.e. onset of post-
natal depression) for all women lost to follow-up. If this was done,
a sensitivity analysis was also performed assuming a positive out-
come (i.e. no postnatal depression) for all women lost to follow-
up.We anticipated that some studies would have used the method
of last observation carried forward (LOCF) to do an ITT analy-
sis. As with all methods of imputation to deal with missing data,
LOCF introduces uncertainty about the reliability of the results:
therefore we have indicated where we have reported LOCF data in
this review. We presented ITT analysis for all primary outcomes.
Where ITT analyses were not available for secondary outcomes,
we reported this in the relevant section of the results.
Assessment of heterogeneity
There were insufficient studies to conduct a meta-analysis. How-
ever, if future updates of this review include sufficient comparable
studies to conduct a meta-analysis, we will assess statistical het-
erogeneity visually by studying the degree of overlap of the confi-
dence intervals for individual studies in a forest plot. We will also
conduct more formal assessments of heterogeneity using a Chi²
test with the P value set at 0.1 (taking into account the fact that
this test has low statistical power when there are few studies). We
will use the I² statistic, and will interpret its results based on the
following overlapping bands, as suggested in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: represents considerable heterogeneity
Assessment of reporting biases
There were insufficient studies to conduct a meta-analysis. How-
ever, if a future update of this review includes ameta-analysis pool-
ing data from 10 or more studies, we will generate a funnel plot
and visually inspect it for asymmetry, which can indicate publica-
tion bias. We will also consider other possible causes of funnel plot
asymmetry (e.g. poor methodological quality of small studies).
Data synthesis
We identified insufficient studies in this review to conduct a meta-
analysis. However, if a future update of this review includes three
of more studies using the same class of antidepressants and the
same comparison group (e.g. placebo), we will perform a meta-
analysis. Due to the anticipation of clinical heterogeneity between
studies, for example in the participant groups included, we will
conduct a random-effects meta-analysis.
Subgroup analysis and investigation of heterogeneity
We were unable to include sufficient studies in this review to con-
duct subgroup analyses or further investigations of heterogeneity.
However, if we identify sufficient data in future updates of this
review we will conduct the following subgroup analyses to inves-
tigate heterogeneity between trials and assess the effectiveness of
the intervention in the following groups.
1. Studies in which women started antidepressants during preg-
nancy versus studies in which women started antidepressants in
the postpartum period, to examine whether the timing of antide-
pressant use influences its effectiveness in preventing postnatal de-
pression.
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2. Studies inwhich all womenhad a history of postnatal depression
versus studies in which women had a history of non-postnatal
depression, to examine whether this influences the effectiveness of
antidepressant prevention of postnatal depression.
Sensitivity analysis
We were unable to include sufficient studies in this review to con-
duct sensitivity analyses. However, if future updates of this review
include sufficient data, we will conduct a priori sensitivity analyses
to examine the robustness of pooled estimates to decisions made
in the methods of this systematic review. We will assess the effects
of excluding studies with the following characteristics.
1. Study quality: excluding studies that had a high risk of bias in
any domain.
2. Blinding: excluding antidepressant versus placebo trials that
were unblinded.
3. Attrition: excluding studies with more than 20% drop-out.
4. Validation: excluding outcomes based on non-validated assess-
ments.
We also planned additional sensitivity analyses to examine missing
data (described in Dealing with missing data). If studies have not
performed ITT analyses, we will calculate the RR assuming a neg-
ative outcome (i.e. onset of postnatal depression) for all women
lost to follow-up and a sensitivity analysis assuming a positive out-
come (i.e. no postnatal depression) for all women lost to follow-
up.
’Summary of findings’ tables
We have produced ’Summary of findings’ tables for the key find-
ings of the review for all main comparisons in the time frame
of intermediate effects (12 to 24 weeks) (Summary of findings
for the main comparison; Summary of findings 2). The tables
present findings for primary and secondary outcomes (see Types
of outcome measures) including the standardised effect size esti-
mates (with 95% confidence intervals), number of studies and
participants, and the quality of evidence based on standards of the
GRADE working group (see Balshem 2011). The secondary out-
comes included in the ’Summary of findings’ tables are: accept-
ability of treatment, overall maternal satisfaction, improvement
in the maternal relationship with the baby, and establishment or
continuation of breastfeeding.
R E S U L T S
Description of studies
Results of the search
The searches were carried out to 13 February 2018. They identi-
fied 396 references, of which 320 remained after de-duplication.
Two review authors (LT and EM) independently screened the ti-
tles and abstracts of these records and excluded 303 which did not
meet the inclusion criteria. We retrieved and inspected the full-
text papers (or trial protocols) for the remaining 17 study reports.
We excluded a total of six of these for not meeting our inclusion
criteria: one because the trial terminated due to low recruitment
(NCT02235064); and the remaining five reports (four studies) as
these assessed treatment rather than prevention of postnatal de-
pression or continuation with discontinuation of antidepressants
during pregnancy for the prevention of perinatal (i.e. antenatal or
postnatal) depression rather than examining initiation of antide-
pressants for the prevention of postnatal depression. There are two
primary study reports with an additional eight secondary publi-
cations for the two trials which meet the inclusion criteria and
are included in the review. In addition, there is one completed
but unpublished study (NCT00276900) (see Characteristics of
studies awaiting classification). We contacted the trial investigator
for additional information but unfortunately it was not possible
for her to respond to our request due to the period of time that
has elapsed since the included trials were conducted. The study
selection process is detailed in our PRISMA flow diagram (Figure
1).
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Figure 1. Study flow diagram.
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Included studies
We included two studies in this review (Wisner 2001 and Wisner
2004), with characteristics as follows (see also Characteristics of
included studies).
Design
Both studies were double-blind, randomised controlled trials com-
paring an antidepressant medication with a placebo. We found no
eligible cluster-randomised or cross-over trials.
Sample sizes
Wisner 2001 had a sample size of 56 participants at baseline, of
whom 51 were included in their analyses (26 participants taking
nortriptyline and 25 participants taking placebo). Wisner 2004
had a sample size of 25 women at baseline with 22 included in the
analyses (14 women in the sertraline arm and 8 in the placebo arm,
recruited in a 2:1 intervention to placebo ratio). In both studies,
women were excluded from the analyses if they refused to take the
study drug after randomisation. Three women randomised to ser-
traline who never took themedication were excluded fromWisner
2004, and four women were excluded fromWisner 2001 for refus-
ing to take the study drug (treatment allocation unknown).Wisner
2001 also excluded one participant (randomised to nortriptyline)
who developed mania in the first week postpartum from the anal-
yses.
Setting
Both studies recruited pregnant women (up to 35 weeks’ gesta-
tion) who were not depressed in the index pregnancy; and both
began medication in the immediate postpartum period. In both
trials, the first dose of the antidepressant or placebo medication
was provided for women in the hospital following delivery. For
both studies, participants had to be aged 21 to 45 years, and not
be depressed in the index pregnancy but have at least one previous
episode of postnatal depression within five years prior to enrol-
ment.Wisner 2001 stated that to be considered to be postnatal de-
pression, symptom onset must have been within three months of a
live birth. Both studies excluded women with previous episodes of
psychosis and bipolar disorder, other current Axis I diagnoses (ex-
cept for generalised anxiety and panic disorder) and antisocial or
borderline personality disorders. Women receiving psychotherapy
or who used psychotropic medications after the first trimester of
the index pregnancy were also excluded from both studies. Wisner
2004 also excluded women with an incomplete blood count or
abnormal results from thyroid tests.
Interventions
Wisner 2001 examined nortriptyline (a tricyclic antidepressant)
and Wisner 2004 examined sertraline (a selective serotonin re-
uptake inhibitor (SSRI)). In both studies the antidepressant was
taken as soon as possible after delivery, ideally within 24 hours.
In Wisner 2001, the dose of nortriptyline was increased from
20 mg/day to 70 mg/day over the first week. A dose of 75 mg/
day was then maintained to day 21, after which the dose was
calculated individually for each participant, based on their serum
level measured on day 14. The dose was then adjusted over time
based on further serum levels and side effects data, in order to
maintain the nortriptyline serum level between 50 mg/day and
150 mg/mL with the optimum set at 80 mg/day to 120 mg/mL.
The dose was then tapered through weeks 17 to 20 at a rate of 33%
per week. Doses (three capsules of either nortriptyline or placebo)
were taken once daily at bedtime.
In Wisner 2004, the dose of sertraline was originally started at
50 mg/day. However, a dose reduction was recommended by the
non-blind side effects monitoring team after the first two study
participants withdrew after experiencing severe headaches. There-
fore, for all remaining participants the dose began with 25 mg/
day increased to 50 mg/day over the first four weeks of treatment
and up to 75 mg/day over weeks 5 to 17. From week 17, the dose
of sertraline was tapered and treatment was discontinued at week
20.
Outcome
Primary outcome assessment
In both studies, onset of postnatal depression was determined
through screening with the Hamilton Rating Scale for Depression
(HAM-D) followed by a diagnostic interview. InWisner 2001, the
HAM-D was administered to all women weekly. If a participant
scored 15 or more on the HAM-D they were evaluated a second
time within seven days. If they scored 15 or more on the HAM-
D again and met research diagnostic criteria for major depression
on both occasions, the principal investigator and an independent
board-certified psychiatrist evaluated the participant. Both psychi-
atrists were blinded to participant allocation (i.e. antidepressants
or placebo). Women were classified as having depression if both
psychiatrists reached a diagnosis of major depressive disorder.
A similar but simpler approach was used in Wisner 2004. If a
woman scored 15 or more on the HAM-D on two occasions,
one week apart, she was assessed by a single psychiatrist who was
associated with the study but blinded to participant allocation. In
both studies, the treatment period lasted 17 weeks and primary
outcomes were assessed at the end of the treatment period (i.e. 17
weeks post randomisation), prior to themedication being tapered.
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Both studies assessed symptoms of mania weekly and assessed side
effects with the Asberg Side Effects rating scale. Adverse events
occurring during both studies were also reported.
Secondary outcome assessment
There was no direct assessment of the acceptability of treatment in
either study:we used the number of participantswithdrawing from
each treatment group as an indirect measure of acceptability. Nei-
ther Wisner 2001 nor Wisner 2004 provided information about
the cognitive and emotional development of the infant, overall
maternal satisfaction, maternal relationship with the infant, the
mother’s ability to carry out daily activities, breastfeeding, neglect
or abuse of the infant or the effect on marital and family relation-
ships.
Excluded studies
We excluded two records during full-text screening, as they evalu-
ated the treatment rather than prevention of postnatal depression.
For full details of these studies see Characteristics of excluded
studies.
New studies found at this update
No new studies have been included in the review in this update.
Studies awaiting classification
No studies are awaiting classification.
Ongoing studies
Two RCTs are currently ongoing. Both studies are investigating
the use of sertraline to prevent postnatal depression compared
with a placebo control. One study has completed recruitment,
but results of the trial are not yet available (NCT00276900). The
second RCT is currently recruiting (NCT02235064). Future up-
dates of this review should consider these studies for inclusion. See
Characteristics of ongoing studies for further details.
Risk of bias in included studies
TheCharacteristics of included studies section provides full details
of risk of bias judgements for each study.Graphical representations
of the overall risk of bias in included studies are presented in Figure
2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Random Sequence Generation
Neither study report gave details of the method of randomisation.
Allocation Concealment
Neither study provided information about allocation conceal-
ment.
Blinding
Blinding of participants and personnel
Both studies were conducted with a double-blind design (partici-
pants and study personnel were blinded to treatment allocation).
Blinding was facilitated in both cases by providing placebo and
antidepressant medication in identical forms. Blinded study staff
were questioned to assess the integrity of blinding in both studies.
In Wisner 2001, staff did not successfully identify drug assign-
ment more often than chance, other than the nurse monitoring
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side effects. In Wisner 2004, no staff or participants were more
successful than chance at identifying allocation. Both studies were
rated as low risk of bias for blinding of participants and personnel.
Blinding of outcome assessment
Both studies were rated as having low risk of bias for the blind-
ing of outcome assessment, as mood symptom raters and the psy-
chiatrists assessing outcomes were blind to participant group al-
location. Outcome assessors were included in the assessment of
blinding described above and did not successfully identify drug
assignment more often than chance.
Incomplete outcome data
In Wisner 2001, four participants declined to take the study drug
after randomisation and one participant developed mania in the
first week postpartum: none of these five were included in the anal-
ysis. This means that analyses were not performed on a ’once ran-
domised, always analyse’ basis. In addition, one other participant
randomised to nortriptyline was lost to follow-up from the study
and three participants withdrew from the placebo arm (due to side
effects, personal reasons and pregnancy). These participants were
included in the analyses (but censored at the week they withdrew
from the study).
In Wisner 2004, three participants assigned to sertraline who did
not take any medication were not included in the analyses (also
therefore not performed on a ’once randomised, always analyse’
basis). Of those who took sertraline, two withdrew due to side
effects and one due to an episode of hypomania, but these par-
ticipants were included in the analyses. It is not explicitly stated
how many participants withdrew from the placebo arm but it is
recorded that there was no significant difference between groups
for the number of participants withdrawing from the study. The
risk of bias related to incomplete outcome data in both studies
was therefore rated as high owing to the exclusion of participants
from the analyses and relatively high proportions of drop-outs for
the small sample sizes.
Selective reporting
Protocolswere not available for either study.The risk of bias related
to selective reporting was therefore unclear for both studies.
Other potential sources of bias
Both studies assessed adherence tomedicationwith frequent serum
level tests. In theWisner 2001 study, five participants randomised
to nortriptyline were considered non-adherent (in addition to the
four who withdrew without taking the study drug). Sensitivity
analyses showed that excluding these non-adherent participants
did not significantly alter the results. In the Wisner 2004 study,
serum levels indicated that all participants randomised to sertraline
and included in the analyses were adherent. The risk of bias related
to adherence to medication therefore appears to be low in both
studies.
Effects of interventions
See: Summary of findings for the main comparison
Nortripyline for the prevention of postnatal depression; Summary
of findings 2 Sertraline for the prevention of postnatal depression
Comparison 1: nortriptyline versus placebo
One study contributed data to this comparison (Wisner 2001).
Fifty-six participants were randomised in this study and 51 partic-
ipants were included in their analyses (26 assigned to nortriptyline
and 25 assigned to placebo). See also Summary of findings for the
main comparison. It was not possible to obtain the necessary data
to analyse this study on a ’once randomised, always analyse’ basis.
Primary outcomes
1.1 Number of participants who developed depression
during the first six months postpartum
Wisner 2001 reported that nortriptyline was not more effective
than placebo in preventing postnatal major depressive disorder
(RR 0.96, 95%CI 0.36 to 2.59, P = 0.9381) after a 17-week treat-
ment period (see Figure 4). Six out of 26 women in the nortripty-
line group developed postnatal depression compared with six out
of 25 women in the placebo group. Data from participants who
withdrew from the study were censored at the week theywithdrew.
Wisner 2001 also reported that time to onset of depression did
not differ between the nortriptyline and placebo groups (exact log-
rank ≤ 0.00, exact P = 0.83). From the serum level tests, the trial
authors determined that five women randomised to nortriptyline
were non-adherent; censoring these participants at the point of
non-adherence did not change the findings of the study.
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Figure 4. Forest plot of comparison: 1 Nortriptyline versus placebo, outcome: 1.1 Recurrence of
postpartum major depressive disorder.
1.2 Adverse effects experienced by mother and/or foetus or
nursing baby
One woman assigned to nortriptyline developed mania within
the first week, but no other specific adverse events were reported.
The only side effect reported more frequently in the nortriptyline
than placebo group was constipation (78% among women taking
nortriptyline and 22% among women taking placebo; Fischer’s
exact test P <0.001). The proportion ofwomen experiencing other
side effects was not reported.
Secondary outcomes
1.3 Acceptability of treatment
Acceptability of treatment was not assessed directly. However, in-
formation regarding the number of participants dropping out or
being lost to follow-up may provide some indication of accept-
ability. In this study one woman was lost to follow-up from the
nortriptyline arm (and one women in the nortriptyline arm with-
drew after developing mania in the first postpartum week) and
three withdrew from the placebo arm (owing to side effects, per-
sonal reasons and pregnancy). Four participants declined to take
the study drug after randomisation.
1.4 Cognitive and emotional development of the infant/child
No data available.
1.5 Overall maternal satisfaction
No data available.
1.6 Improvement in the maternal relationship with the baby
No data available.
1.7 Improvement in the ability of the mother to carry out
daily activities and in her social functioning
No data available.
1.8 Establishment or continuation of breastfeeding
No data available.
1.9 Prevention of neglect or abuse of the baby
No data available.
1.10 Effect on marital and family relationships
No data available.
Comparison 2: sertraline versus placebo
One study contributed data for this comparison (Wisner 2004).
Twenty-five participants were randomised into this study and 22
were included in their analyses (14 assigned to sertraline and 8 as-
signed to placebo). See also Summary of findings 2. Three women
assigned to sertraline were excluded from the analyses because they
did not take the study medication. Additional analyses were con-
ducted on a ’once randomised, always analyse’ basis for this review.
Primary outcomes
2.1 Number of participants who developed depression
during the first six months postpartum
Wisner 2004 reported that sertraline was more effective than
placebo in preventing postnatal major depressive disorder after
a 17-week treatment period (see Figure 5). One (7%) of the 14
women who took sertraline developed depression compared with
four (50%) of the eight women taking placebo (P = 0.04, Fisher
exact test). The difference in rates of postnatal depression was 0.43
(95% exact CI = −0.01 to 0.84). The RR was calculated for this
review and provided evidence of a trend but was below the cut-
off for statistical significance (RR 0.14, 95% CI 0.02 to 1.07, P
= 0.058). For this review, we also recalculated the RR on a ’once
randomised, always analyse’ basis including an additional three
participants who were randomised to sertraline but excluded from
the trial analyses for never taking the medication. Including these
three participants and assuming a negative outcome (i.e. onset of
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postnatal depression) for those not included in the original anal-
yses, we calculated the RR to be 0.47 (95% CI 0.16 to 1.42, P
= 0.18). Assuming a positive outcome for these three participants
(i.e. no onset of postnatal depression), we calculated the RR to be
0.12 (95%CI 0.02 to 0.89, P = 0.038). Wisner 2004 also reported
that the time to recurrence differed between the sertraline and
placebo groups (exact Gehan-Wilcoxon P = 0.02). The observed
hazard ratio for time to recurrence of depression was 0.11 (95%
exact CI = 0.02 to 1.02).
Figure 5. Forest plot of comparison: 2 Sertraline versus placebo, outcome: 2.1 Recurrence of postpartum
major depressive disorde.
2.2 Adverse effects experienced by mother and/or foetus or
nursing baby
One woman taking sertraline experienced a hypomanic episode.
The first two participants experienced severe headaches causing
them to withdraw from the study which led to the original dosage
of sertraline being reduced from 50 mg to 25 mg (see Description
of studies). Two side effects were found to be significantly more
frequent in the group taking sertraline: eight (57%) of the women
taking sertraline and one (13%) of the women taking placebo ex-
perienceddizziness (P =0.05Freeman-Halton extension of Fisher’s
exact test); and drowsiness was also found to be more frequent
in the sertraline arm, in which it was experienced by 14 women
(100%), compared with 4 women (50%) in the placebo arm (P =
0.02; Freeman-Halton extension of Fisher’s exact test).
Secondary outcomes
2.3 Acceptability of treatment
Wisner 2004 did not report a direct measure of acceptability;
however no difference was found between the antidepressant and
placebo groups in the number of women withdrawing from the
study (P = 0.35, Fisher’s exact test).
2.4 Cognitive and emotional development of the infant/child
No data available.
2.5 Overall maternal satisfaction
No data available.
2.6 Improvement in the maternal relationship with the baby
No data available.
2.7 Improvement in the ability of the mother to carry out
daily activities and in her social functioning
No data available.
2.8 Establishment or continuation of breastfeeding
No data available.
2.9 Prevention of neglect or abuse of the baby
No data available.
2.10 Effect on marital and family relationships
No data available.
Subgroup analyses
We were unable to conduct the planned subgroup analyses due to
the small number of included studies.
20Antidepressants for preventing postnatal depression (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sensitivity analyses
We were unable to conduct the planned sensitivity analyses due
to the small number of included studies.
Reporting bias
There were insufficient studies to assess reporting bias.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Sertraline for the prevention of postnatal depression
Patient or population: women with a history of postnatal depression
Intervention: sertraline
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Selective serotonin re-
uptake inhibitors
Postnatal depression
(17 weeks)
500 per 1000 70 per 1000
(10 to 535)
RR 0.14
(0.02 to 1.07)
22
(1 study)
⊕©©©
very low2,3
Adverse effects expe-
rienced by mother and/
or fetus or nursing baby
22
(1 study)
⊕©©©
very low2,3
1 woman taking sertra-
line had a hypomanic
episode.
2 side ef fects (dizzi-
ness and drowsiness)
were more common
among women taking
sertraline than women
taking placebo
Acceptability of treat-
ment (17 weeks)
22
(1 study)
⊕©©©
very low2,3
Acceptability of treat-
ment was not as-
sessed direct ly but no
dif ference was found
between the ant ide-
pressant and placebo
groups in the number
of women withdrawing
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f rom the study (P = 0.
35, Fisher’s exact test)
Overall maternal satis-
faction (17 weeks)
No data available
Improvement in the
maternal relationship
with the baby (17
weeks)
No data available
Establishment or con-
tinuation of breast-
feeding (17 weeks)
No data available
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Assumed risk calculated as the proport ion of women on placebo with the outcome (postnatal depression) mult iplied by 1000
2Downgraded due to high risk of bias in 1 domain (incomplete outcome data)
3Downgraded twice due to imprecision (only 1 small study available for this comparison)
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D I S C U S S I O N
Summary of main results
We included two RCTs examining the effectiveness of antidepres-
sants for the prevention of postnatal depression in this review.
All participants in both studies had a history of postnatal depres-
sion and were not taking antidepressant medication at baseline.
There were insufficient studies to conduct a meta-analysis. The
first study provided no evidence that nortriptyline was more effec-
tive than placebo in preventing postnatal depression (see Summary
of findings for the main comparison). The second study found
some evidence that sertraline may be effective in preventing post-
natal depression (see Summary of findings 2) but the sample size
was extremely small and the risk ratio, calculated for this review,
was just below statistical significance. The low statistical power of
this study means that we cannot exclude the possibility that sertra-
line is no different from placebo in its effectiveness for preventing
postnatal depression, but we also cannot exclude the possibility
that sertraline has a substantial preventative effect. It is not possi-
ble to draw conclusions about the effectiveness of antidepressants
for the prevention of postnatal depression until more studies are
conducted including greater number of participants.
Overall completeness and applicability of
evidence
This review includes two trials comparing antidepressants with
placebo but we identified no studies comparing antidepressants
with other preventative interventions or with standard care. Both
trials examined a 17-week treatment period with primary out-
comes assessed immediately post treatment, meaning that it is not
possible to draw conclusions about the optimal duration of antide-
pressant treatment for the prevention of postnatal depression. In
addition, neither study addressed any of the secondary outcomes
of this review regarding the effect of antidepressants on the infant
or other family members, or secondary outcomes for the mother
such as social functioning. In addition, neither study reported on
the severity or course of depressive episodes, which means it is
not possible to examine whether antidepressant use was associated
with a milder symptom profile and course among women who did
develop postnatal depression.
Recruitment rates were low and, where reported in Wisner 2001,
under half of the women eligible for the study took part. This
reflects many women’s reluctance to take antidepressants in the
perinatal period, observed in other studies and systematic reviews
(Turner 2008; Molyneaux 2014), which may be particularly the
case for prevention rather than treatment of depression. This issue
was also highlighted by one trial identified through the searches of
ClinicalTrials.gov which would have been eligible for this review
but was terminated due to slow recruitment (NCT02235064).
In both of the studies that we included in this review, women
were only eligible if they had a history of postnatal depression.
This is unlikely to be a major limitation to the applicability of
this evidence to clinical practice, as prophylactic antidepressant
use in the postnatal period is most likely to be considered for this
group of women. No studies were identified for this review in
which antidepressants were started during pregnancy as a preven-
tative intervention. Many women will be very unwilling to start
antidepressants in pregnancy if they are not currently depressed;
however, some women with a recent history of major depressive
episodes may stay on their antidepressants throughout pregnancy
and the postnatal period to prevent relapse.
This update of the review identified no new studies, despite the
last published version of this review being completed over a decade
ago. This suggests significant barriers to the completion of research
in this area which may, for example, be related to the difficul-
ties in recruiting pregnant women to randomised trials and the
reluctance of many women to take antidepressants during preg-
nancy and breastfeeding. In addition, the lack of recent trials in
this area is likely to reflect the fact that research and clinical prac-
tice is moving away from a specific focus on the prevention of
postnatal depression to also consider the prevention and treatment
of antenatal depression, including the continuation of antidepres-
sants throughout pregnancy to prevent relapse of depression dur-
ing pregnancy or the postnatal period. For example, one ongoing
study is comparing continuation of antidepressants throughout
pregnancy with preventative cognitive therapy and gradual dis-
continuation of antidepressants (Molenaar 2016). This pragmatic
study would not meet the inclusion criteria for this systematic
review, but should provide important data on whether continu-
ation of antidepressants throughout pregnancy prevents relapse
of depression. To maximise the clinical utility of future system-
atic reviews in this area, we recommend that reviews should ex-
amine the effectiveness of antidepressants for the prevention of
perinatal depression more broadly (i.e. antenatal as well as post-
natal), and should include trials investigating the effectiveness of
the continuation of antidepressant use for the prevention of peri-
natal depression. Future studies should also consider the sever-
ity of women’s previous depression episodes, potentially stratify-
ing by this in their randomisation and analyses. As described in
Agreements and disagreements with other studies or reviews, evi-
dence suggests that recurrence of depression after discontinuation
of antidepressants may be more likely for women with a history
of severe, or recent, episodes of depression.
Quality of the evidence
The studies included in this review do not allow a robust exami-
nation of the effectiveness of antidepressants in preventing post-
natal depression. Only two eligible studies were identified, which
included 73 participants in total in their main analyses. Both stud-
ies were generally well conducted, with effective double-blind-
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ing for example; however neither trial was analysed on a ’once
randomised, always analyse’ basis as women who dropped out of
the study after randomisation before taking any medication were
excluded from the analyses. There was also drop-out from both
studies and, although the numbers dropping out were not high,
this may have influenced results owing to the small overall sample
sizes. Wisner 2001 stated that their results (that nortriptyline was
not effective in preventing postnatal depression) were inconsistent
with a pilot trial they had conducted on this topic that was un-
blinded and not randomised, which highlights the importance of
high-quality study methodology in this field. There was also in-
consistency between the findings in Wisner 2001 and in Wisner
2004. Finally, both studies were conducted by the same research
team, which is a limitation of the evidence base to date. Overall,
the results of the studies included in this review do not allow con-
clusions to be drawn about the effectiveness of antidepressants for
postnatal depression, but do highlight that it may be important to
consider the effectiveness of different antidepressants separately.
Potential biases in the review process
Weminimised potential bias in the selection of studies by employ-
ing consistent and predefined eligibility criteria. In order to reduce
potential biases we also predefined our methods for extracting data
and conducting risk of bias assessment; and conducted them in
accordance with guidance in theCochraneHandbook for Systematic
Reviews of Interventions (Higgins 2011). For example study screen-
ing, data extraction and risk of bias assessment were performed
by two review authors independently. Publication bias may have
influenced the findings of this review, as we did not search the
grey literature and studies may be more likely to be published if
they find that antidepressants are effective in preventing postnatal
depression. However, we did search clinical trials’ registries, which
enabled us to identify relevant unpublished RCTs; this should
limit any impact of publication bias. Overall, the review process is
unlikely to have been biased, but it was limited by the extremely
small number of relevant studies identified.
Agreements and disagreements with other
studies or reviews
Previous systematic reviews of RCTs have shown that psycholog-
ical and psychosocial interventions can be effective in preventing
postnatal depression (Morrell 2016); and that antidepressants can
reduce the risk of relapse among non-pregnant adults with recent
episodes of depression (Geddes 2003). There is also evidence from
a Cochrane Review that antidepressants can be effective for treat-
ing postnatal depression (Molyneaux 2014). However, there have
been very few trials of antidepressant prevention of postnatal de-
pression and only two eligible RCTs were identified for this review.
One of these trials suggested that antidepressants may be effective
in preventing postnatal depression whereas the other trial found
no evidence for this.
Related observational studies examining relapse following discon-
tinuation of antidepressants during pregnancy have also had in-
consistent findings. One prospective cohort study found a signif-
icantly higher rate of relapse among women who discontinued
antidepressant medication during pregnancy than women who
continued antidepressants (hazard ratio (HR) 5.0, 95% CI 2.8
to 9.1) (Cohen 2006). In contrast, another prospective cohort
study found no association between antidepressant discontinua-
tion and rate of relapse of depression during pregnancy or the first
two months after delivery (adjusted HR 0.88, 95% CI 0.51 to
1.50) (Yonkers 2011). The difference in findings between these
two studies may reflect differing severity of depression among par-
ticipants. Yonkers 2011 recruited from obstetricians and general
hospital settings, and found no difference in the rate of relapse re-
lated to antidepressant discontinuation. In contrast, Cohen 2006
recruited from specialist mental health centres and participants are
therefore likely to have had more severe disorders (and were more
likely to relapse following discontinuation of antidepressants). The
importance of ensuring that treatment needs are met for women
with severe depression or other mental disorders during pregnancy
and the postnatal period was also highlighted in a recent study
using UK data from women in contact with psychiatric services,
which found that suicides in the perinatal period are more likely
to occur among women not receiving any treatment at the time
of death (Khalifeh 2016).
This Cochrane Review is an update and did not include any ad-
ditional studies beyond the previous version of this review, pub-
lished in 2005. The overall conclusion of the original version of
this review remains: it is not possible to conclude whether or not
antidepressants are effective in preventing postnatal depression.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This systematic review only identified two completed studies of
antidepressant prevention of postnatal depression. All participants
in both studies had a history of postnatal depression, and were
therefore at higher risk of experiencing postnatal depression again.
It is not possible from these two studies to draw conclusions about
the effectiveness of antidepressants in preventing postnatal depres-
sion. Decisions around the use of antidepressants for preventing
postnatal depression need to bemade through individual risk-ben-
efit analyses which take into account the preferences of the woman
as well as severity and recency of previous episodes of depression.
Implications for research
RCTs with larger sample sizes and longer-term follow-up are
needed. It is critical that future trials assess side effects of antide-
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pressant use for the fetus or infant, as well as for the mother. Both
of the trials eligible for this review compared antidepressants with
placebo, and studies comparing the effectiveness of antidepressants
with evidence-based psychological or psychosocial preventative in-
terventions are also needed (such as cognitive behavioural ther-
apy or interventions based on a person-centred approach; Morrell
2016). No new studies were eligible for this update of the review,
despite the last published version being completed over a decade
ago. Future reviews in this area could broaden their scope to exam-
ine the effectiveness of antidepressants for the prevention of peri-
natal depression (i.e. antenatal as well as postnatal depression), and
include trials investigating the effectiveness of the continuation
of antidepressant use for the prevention of relapse of depression
during the perinatal period.
A C K N OW L E D G E M E N T S
The authors would like to thank the Cochrane Common Mental
Disorders Group for their advice with this review.
CRG Funding Acknowledgement
The National Institute for Health Research (NIHR) is the largest
single funder of the Cochrane CommonMental Disorders Group.
Disclaimer
The views and opinions expressed herein are those of the authors
and do not necessarily reflect those of the NIHR, NHS or the
Department of Health.
R E F E R E N C E S
References to studies included in this review
Wisner 2001 {published data only}
Gracious BL, Hanusa BH, Wisner KL, Peindl KS, Perel
JM. Weight changes in postpartum women with remitted
depression. Journal of Clinical Psychiatry 2005;66(3):291–3.
Peindl KS. The use of nortriptyline for prevention of
postpartum depression in a high-risk group of women.
152nd Annual Meeting of the American Psychiatric
Association, 1999 May 15-20, Washington, DC. 1999.
Peindl KS, Wisner KL. Successful recruitment strategies
for women in postpartum mental health trials. Journal of
Psychiatric Research 2003;37(2):117–25.
Peindl KS, Wisner KL, Hanusa BH, Peindl KS. Identifying
depression in the first postpartum year: Guidelines for
office-based screening and referral. Journal of Affective
Disorders 2004;80(1):37–44.
Wisner KL. Prevention and treatment of postpartum
mood disorders. 152nd Annual Meeting of the American
Psychiatric Association, 1999 May 15-20, Washington, DC.
1999.
∗ Wisner KL, Perel JM, Peindl KS, Hanusa BH, Findling
RL, Rapport D. Prevention of recurrent postpartum
depression: a randomized clinical trial. Journal of Clinical
Psychiatry 2001;62(2):82–6.
Wisner 2004 {published data only}
Gracious BL, Hanusa BH, Wisner KL, Peindl KS, Perel
JM. Weight changes in postpartum women with remitted
depression. Journal of Clinical Psychiatry 2005;66(3):291–3.
Sunder KR, Wisner KL, Hanusa BH, Perel JM. Postpartum
depression recurrence versus discontinuation syndrome:
observations from a randomized controlled trial. Journal of
Clinical Psychiatry 2004;65(9):1266–8.
Wisner KL, Peindl KS, Perel JM, Hanusa BH, Plontek CM,
Findling RL. Sertraline prevents postpartum depression.
156th Annual Meeting of the American Psychiatric
Association, May 17-22, San Francisco CA. 2003.
∗ Wisner KL, Perel JM, Peindl KS, Hanusa BH, Piontek
CM, Findling RL. Prevention of postpartum depression:
a pilot randomized clinical trial. American Journal of
Psychiatry 2004;161(7):1290–2.
References to studies excluded from this review
Appleby 1997 {published data only}
Appleby L. A controlled study of fluoxetine and cognitive
-behavioural counselling in the treatment of postnatal
depression. European Psychiatry 1998;13 Suppl 4:178s.
Appleby L, Warner R, Whitton A, Faragher B. A controlled
study of fluoxetine and cognitive-behavioural counselling
in the treatment of postnatal depression. BMJ 1997;314
(7085):932–6.
Epperson 1996 {published data only}
Epperson CN, McDougle CJ, Ward-O’Brien D, Price
LH. A controlled study of antidepressant treatment of
postpartum depression. 149th Annual Meeting of the
American Psychiatric Association; 1996 May 4-9; New
York, NY. 1996.
Heath 2000 {published data only}
Heath AC, Yonkers KA, Rush AJ. Paroxetine in the
treatment of postpartum depression. 153rd Annual Meeting
of the American Psychiatric Association, 2000 May 13-18,
Chicago, (IL). 2000.
NCT02235064 {published data only}
Fischer RL, Simpkins GK. Prophylactic Use of
Postpartum Sertraline to Prevent Postpartum Depression.
clinicaltrials.gov/ct2/show/NCT02235064 (accessed 30
October 2017). NCT02235064]
Sharp 2004 {published data only}
Sharp D. Antidepressant drug therapy vs a community-
based psychosocial intervention for the treatment of
26Antidepressants for preventing postnatal depression (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
moderate postnatal depression: a pragmatic randomised
controlled trial. National Research Register 2004.
References to ongoing studies
NCT00276900 {unpublished data only}
Wisner K. Sertraline for the Prevention of Recurrent
Postpartum Depression [Prevention of Recurrent
Postpartum Depression]. clinicaltrials.gov/ct2/show/
NCT00276900 2006.
Additional references
American Psychiatric Association 2013
American Psychiatric Association. Diagnostic and statistical
manual of mental disorders (5th ed.). Washington, DC:
American Psychiatry Association, 2013.
Bland 2000
Bland JM, Altman DG. The odds ratio. BMJ 2000;320
(7247):1468.
Cohen 2006
Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport
DJ, Viguera AC, et al. Relapse of Major Depression During
Pregnancy in Women Who Maintain or Discontinue
Antidepressant Treatment. JAMA 2006;295(5):499.
Cox 1982
Cox J, Connor Y, Kendell RE. Prospective study of the
psychiatric disorders of childbirth. British Journal of
Psychiatry 1982;140:111–7.
Cox 1987
Cox JL, Holden J, Sagovsky R. Detection of postnatal
depression: development of the 10-item Edinburgh
Postnatal Depression Scale (EPDS). British Journal of
Psychiatry 1987;150:782–6.
Dennis 2007
Dennis C-L, Hodnett ED. Psychosocial and psychological
interventions for treating postpartum depression. Cochrane
Database of Systematic Reviews 2007, Issue 10. DOI:
10.1002/14651858.CD006116.pub2
Elbourne 2002
Elbourne DR, Altman DG, Higgins JP, Curtin F,
Worthington HV, Vail A. Meta-analyses involving cross-
over trials: methodological issues. International Journal of
Epidemiology 2002;31(1):140–9.
Fournier 2010
Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S,
Amsterdam JD, Shelton RC, et al. Antidepressant Drug
Effects and Depression Severity. A Patient-Level Meta-
analysis. JAMA 2010;303(1):47–53.
Geddes 2003
Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer
DJ, Frank E, et al. Relapse prevention with antidepressant
drug treatment in depressive disorders: a systematic review.
Lancet 2003;361(9358):653–61.
Higgins 2011
Higgins JP, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011). The Cochrane Collaboration, 2011.
Available from handbook.cochrane.org.
Howard 2006
Howard LM, Boath E, Henshaw C. Antidepressant
Prevention of Postnatal Depression. PLOS Medicine 2006;3
(10):e389.
Howard 2014
Howard LM, Molyneaux E, Dennis C-L, Rochat T, Stein A,
Milgrom J. Non-psychotic mental disorders in the perinatal
period. Lancet 2014;384(9956):1775-88.
Khalifeh 2016
Khalifeh H, Hunt IM, Appleby L, Howard LM. Suicide
in perinatal and non-perinatal women in contact with
psychiatric services: 15 year findings from a UK national
inquiry. Lancet Psychiatry 2016;3(3):233–42.
Molenaar 2016
Molenaar NM, Brouwer ME, Bockting CL, Bonsel GJ,
van der Veere CN, Torij HW, et al. Stop or go? Preventive
cognitive therapy with guided tapering of antidepressants
during pregnancy: study protocol of a pragmatic multicentre
non-inferiority randomized controlled trial. BMC Psychiatry
2016;16:72. DOI: 10.1186/s12888-016-0752-6
Molyneaux 2014
Molyneaux E, Howard LM, McGeown HR, Karia AM,
Trevillion K. Antidepressant treatment for postnatal
depression. Cochrane Database of Systematic Reviews 2014,
Issue 9. DOI: 10.1002/14651858.CD002018.pub2
Morrell 2016
Morrell CJ, Sutcliffe P, Booth A, Stevens J, Scope A,
Stevenson M, et al. A systematic review, evidence synthesis
and meta-analysis of quantitative and qualitative studies
evaluating the clinical effectiveness, the cost-effectiveness,
safety and acceptability of interventions to prevent postnatal
depression. Health Technology Assessment (Winchester,
England) 2016;20(37):1–414.
NICE 2009
NICE. Depression: the Treatment and Management of
Depression in Adults (Update). NICE clinical guideline 90,
2009.
Sharp 2010
Sharp DJ, Chew-Graham C, Tylee A, Lewis G, Howard
L, Anderson I, et al. A pragmatic randomised controlled
trial to compare antidepressants with a community-based
psychosocial intervention for the treatment of women
with postnatal depression: the RESPOND trial. Health
Technology Assessments 2010;14(43):1–153.
Spitzer 1978
Spitzer R, Endicott J, Robins E. Research Diagnostic
Criteria; rationale and reliability. Archives of General
Psychiatry 1978;35(6):773–82.
Stein 2014
Stein A, Pearson RM, Goodman SH, Rapa E, Rahman A,
McCallum M, et al. Effects of perinatal mental disorders on
the fetus and child. Lancet 2014;384(9956):1800–19.
27Antidepressants for preventing postnatal depression (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tierney 2007
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR.
Practical methods for incorporating summary time-to-event
data into meta-analysis. Trials 2007;8:16.
Turner 2008
Turner KM, Sharp D, Folkes L, Chew-Graham C. Women’s
views and experiences of antidepressants as a treatment for
postnatal depression: a qualitative study. Family Practice
2008;25(6):450–5.
Wisner 2013
Wisner KL, Sit DK, McShea MC, Rizzo DM, Zoretich RA,
Hughes CL, et al. Onset timing, thoughts of self-harm,
and diagnoses in postpartum women with screen-positive
depression findings. JAMA Psychiatry 2013;70(4):490–8.
World Health Organization 2004
World Health Organization. The ICD-10 classification of
mental and behavioural disorders: clinical descriptions and
diagnostic guideline. Geneva, World Health Organization,
2004.
Yonkers 2008
Yonkers KA, Lin H, Howell HB, Heath AC, Cohen LS.
Pharmacologic treatment of postpartum women with new-
onset major depressive disorder: a randomized controlled
trial with paroxetine. Journal of Clinical Psychiatry 2008;69
(4):659–65.
Yonkers 2011
Yonkers KA, Gotman N, Smith MV, Forray A, Belanger
K, Brunetto WL, et al. Does antidepressant use attenuate
the risk of a major depressive episode in pregnancy?.
Epidemiology 2011;22(6):848–54.
∗ Indicates the major publication for the study
28Antidepressants for preventing postnatal depression (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Wisner 2001
Methods Study design: randomized controlled trial. Method of randomisation not described
Participants Inclusion criteria:≤ 35 weeks gestation, aged 21 to 45 years, history of at least 1 episode
of postpartum major depressive disorder with onset of symptoms within 3 months of a
live birth (beginning within 5 years prior to study enrolment).
Exclusion criteria: depression during the index pregnancy (i.e. not meeting the research
diagnostic criteria for major depression); antidepressant use after the first trimester of
the index pregnancy; meeting criteria for another axis 1 diagnosis (except generalised
anxiety disorder or panic disorder); meeting criteria for antisocial or borderline person-
ality disorder; history of bipolar disorder or psychosis; continuing use of psychotherapy
or other psychotropic medications
121 women were eligible and 56 women participated. 5 withdrew after randomisation
(1 developed mania in 1st week postpartum and was withdrawn, 4 refused medication)
. 51 women were included in the main analyses (26 randomised to nortriptyline, 25 to
placebo)
Interventions Participants were randomly assigned to either:
(1) Nortriptyline
Treatment protocol: bedtime dose of 3 capsules given as soon as possible after birth,
ideally within 24 hours, increase daily for 1 week postpartum, 20, 30, 40, 50, 60, 70
mg/day and 75 mg to day 21. Serum level from day 14 determined dose from then on
to achieve 50 mg/ml to 150 mg/ml serum level. Dose tapered from week 17 at 33% per
week and discontinued at week 20 postpartum
(2) Placebo
Duration: same protocol for placebo as nortriptyline to help maintain blinding
Outcomes Timepoints for assessment: primary outcomes assessed post-treatment (17 weeks after
randomisation)
Primary outcome: postnatal depression (recurrence and time to recurrence)
Notes Funding source: National Institute of Mental Health (NIMH)
Declarations of interest among the primary researchers: Dr Wisner has received
honoraria from Pfizer and Solvay.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
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Wisner 2001 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “the primary study staff (nurse,
mood symptom rater, coordinator, and
principal investigator) were blind to med-
ication assignment. The medication mon-
itoring function (nurse) was separate from
(and blind to the mood-symptom moni-
toring.” “We monitored the adequacy of
the blind. Except for the nurse who mon-
itored side effects, none of the other per-
sonnel were more successful than chance at
identifying the drug assignment”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind conditions” “The re-
mainder of the protocol ... was identical in
the nortriptyline and placebo groups.”
“The primary study staff (nurse, mood
symptom rater, coordinator, and princi-
pal investigator) were blind to medication
assignment. The medication monitoring
function (nurse) was separate from (and
blind to the mood-symptom monitoring.”
“We monitored the adequacy of the blind.
Except for the nurse who monitored side
effects, none of the other personnel were
more successful than chance at identifying
the drug assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the primary study staff (nurse,
mood symptom rater, coordinator, and
principal investigator) were blind to med-
ication assignment. The medication mon-
itoring function (nurse) was separate from
(and blind to) the mood-symptom mon-
itoring.” “We monitored the adequacy of
the blind. Except for the nurse who mon-
itored side effects, none of the other per-
sonnel were more successful than chance at
identifying the drug assignment”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “of the 56 subjects, 4 declined
to take the study drug after random-
ization. One subject (randomly assigned
to nortriptyline) developed mania in the
first postpartum week. Data for the clin-
ical trial are derived from 51 subjects: 26
who received nortriptyline and 25 who
received placebo. Four subjects withdrew
from the protocol. Three subjects assigned
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Wisner 2001 (Continued)
to placebowithdrewbecause of side-effects,
personal reasons and pregnancy at 4, 10
and 14 weeks, respectively. One subject as-
signed to nortriptyline was lost to follow-
up at week 14. There was no difference in
time to withdrawal of subjects in the nor-
triptyline or placebo groups (exact Savage
test = 0.005, P = 0.91, df = 1).”
Selective reporting (reporting bias) Unclear risk No evidence of selective reporting for im-
portant trial outcomes
Other bias Low risk Quote: “five subjects who took nortripty-
line were defined as noncompliant (serum
nortriptyline level < 50ng/mL). Censoring
of these subjects at the time of noncompli-
ance did not change the results of the re-
currence analysis (exact log-rank < 0.00, P
= 0.83).”
Wisner 2004
Methods Study design: randomized controlled trial. Method of randomisation: randomised in a
2:1 ratio for sertraline vs placebo; other details not given
Participants Inclusion criteria: pregnant women age 21 to 45, healthy with normal thyroid studies
and blood count, < 35 weeks gestation at recruitment, at least 1 episode of postpartum
major depression fulfilling DSM-IV criteria within 5 years of study enrolment.
Exclusion criteria: depression during index pregnancy, use of psychotherapy or psy-
chotropicmedication after 1st trimester, other Axis 1 diagnoses (except general anxiety or
panic disorder), antisocial or borderline personality disorder, or had psychosis or bipolar
disorder
38 eligible women screened, 25 consented to participate, 3 women randomised to sertra-
line never took themedication and were excluded from the analysis. 22 were participants
included in the main analysis (14 randomised to sertraline and 8 randomised to placebo)
Interventions Sertraline - single post-breakfast dose in 2 identical opaque gelatin capsules. Same pro-
tocol for placebo to help maintain blinding
Outcomes Timepoints for Assessment: primary outcomes assessed post-treatment (17 weeks after
randomisation)
Primary outcome: postnatal depression (recurrence and time to recurrence)
Notes Funding source: National Institute of Mental Health (NIMH)
Declarations of interest among the primary researchers: DrWisner is on the speaker’s
bureau for Pfizer Inc, and the sertraline used in this study was donated by Pfizer
Risk of bias
31Antidepressants for preventing postnatal depression (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wisner 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “the blind was continued until all
subjects completed the protocol”
“Sertraline or placebo was given as a single
post-breakfast dose in two identical opaque
gelatin capsules”
“None of the personnel or subjects was
more successful than chance at identifying
the drug assignment. The rates of agree-
ment with the assigned condition ranged
from 38% (for the blinded mood asses-
sors) to 71% (for the side effects monitors),
which did not differ significantly from the
expected 44%-57% (Fisher’s exact test, P =
0.14-0.53).”
“If the subject had a Hamilton depression
scale score of 15 or higher on two occasions
1week apart, shewas evaluated by a blinded
psychiatrist”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the blind was continued until all
subjects completed the protocol”
“Sertraline or placebo was given as a single
post-breakfast dose in two identical opaque
gelatin capsules”
“None of the personnel or subjects was
more successful than chance at identifying
the drug assignment. The rates of agree-
ment with the assigned condition ranged
from 38% (for the blinded mood asses-
sors) to 71% (for the side effects monitors),
which did not differ significantly from the
expected 44%-57% (Fisher’s exact test, P =
0.14-0.53).”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “if the subject had a Hamilton de-
pression scale score of 15 or higher on two
occasions 1 week apart, she was evaluated
by a blinded psychiatrist”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “there was no difference in the
number of women who withdrew from the
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Wisner 2004 (Continued)
study (P = 0.35, Fisher’s exact test) or in
the time to withdrawal (P = 0.85, Freeman-
Halton extension of Fisher’s exact test) be-
tween subjects in the sertraline and placebo
groups... In the 14 women assigned to ser-
traline, the one recurrence becamemanifest
at week 17. Two women withdrew rapidly
because of headaches, which resulted in the
dose change already described. One sub-
ject was removed because of hypomania,
and nine women completed the random-
ized clinical trial without recurrence.”
Selective reporting (reporting bias) Unclear risk No evidence of selective reporting for im-
portant trial outcomes
Other bias Low risk Quote: “the women in the study were com-
pliant, as evidenced by ranges of maternal
serum sertraline andN-desmethylsertraline
levels of 23-48 and 36-66 ng/ml, respec-
tively, across samples from the 8 weeks of
collection.”
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Appleby 1997 Treatment study
Epperson 1996 Treatment study
Heath 2000 Treatment study
NCT02235064 Terminated early due to slow recruitment; no available data
Sharp 2004 Treatment study
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Characteristics of ongoing studies [ordered by study ID]
NCT00276900
Trial name or title
Methods Double-blind, placebo-controlled randomised controlled trial
Participants Estimated enrolment: 300
Interventions Sertraline or placebo
Outcomes Primary outcome: depressive symptoms (measured at 24 and 52 weeks postpartum). Secondary outcome:
functioning (measured at 24 and 52 weeks postpartum)
Starting date
Contact information
Notes This study is led by Katherine Wisner in the USA. The ClinicalTrials.gov record states that data collection is
completed but it was not possible to obtain additional information about this study from the lead researcher
34Antidepressants for preventing postnatal depression (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Nortriptyline versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence of postpartum major
depressive disorder
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 2. Sertraline versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence of postpartum major
depressive disorde
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Nortriptyline versus placebo, Outcome 1 Recurrence of postpartum major
depressive disorder.
Review: Antidepressants for preventing postnatal depression
Comparison: 1 Nortriptyline versus placebo
Outcome: 1 Recurrence of postpartum major depressive disorder
Study or subgroup Nortriptyline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wisner 2001 6/26 6/25 0.96 [ 0.36, 2.59 ]
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours nortriptyline Favours placebo
35Antidepressants for preventing postnatal depression (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Sertraline versus placebo, Outcome 1 Recurrence of postpartum major
depressive disorde.
Review: Antidepressants for preventing postnatal depression
Comparison: 2 Sertraline versus placebo
Outcome: 1 Recurrence of postpartum major depressive disorde
Study or subgroup Sertraline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wisner 2004 1/14 4/8 0.14 [ 0.02, 1.07 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours sertraline Favours placebo
A P P E N D I C E S
Appendix 1. CCDANCTR update search - Feb 2018
#1. antidepress* or anti-depress* or “anti depress*” or MAOI* or RIMA* or “monoamine oxidase inhibit*” or ((serotonin or nore-
pinephrine or noradrenaline or neurotransmitter* or dopamin*) NEAR (uptake or reuptake or re-uptake or “re uptake”)) or SSRI* or
SNRI* or NARI* or SARI* or NDRI* or TCA* or tricyclic* or tetracyclic*
#2. Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Befloxatone
or Benactyzine or Binospirone or Brofaromine or (Bupropion or Amfebutamone) or Butriptyline or Caroxazone or Cianopramine or
Cilobamine or Cimoxatone or Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine) or Clorgyline
or Clovoxamine or (CX157 or Tyrima) or Demexiptiline or Deprenyl or (Desipramine* or Pertofrane) or Desvenlafaxine or Dibenzepin
or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine or DVS-233
#3. Escitalopram or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or (Hyperforin or Hypericum or “St
John*”) or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran or Lofepramine* or (“Lu
AA21004” or Vortioxetine) or “Lu AA24530” or (LY2216684 or Edivoxetine) or Maprotiline or Melitracen or Metapramine or
Mianserin orMilnacipran or Minaprine orMirtazapine or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine
or Norfenfluramine or Nortriptylin* or Noxiptilin*
#4. Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or Pizotyline or
Propizepine or Protriptylin* or Quinupramine or Reboxetine or Rolipram or Scopolamine or Selegiline or Sertraline or Setiptiline or
Teciptiline or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromin* or Trazodone or Trimipramine or Venlafaxine or Viloxazine
or Vilazodone or Viqualine or Zalospirone
#5. (#1 or #2 or #3 or #4 or #5)
#6. (depress* or dysthymi* or “adjustment disorder*” or “mood disorder*” or “affective disorder*” or “affective symptoms”) AND
(postpartum or “post partum” or post-partum or postnatal or “post natal” or post-natal or puerper*)
#7. (#5 and #6)
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Appendix 2. Earlier searches conducted to June 2007
Earlier searches, conducted for the first version of this review used the following search strategies (to 11-June-2007):
1. TheCCDANCTR-Studies Register was searched using the following controlled search terms:
Diagnosis = Depression, Postpartum
AND
Intervention = (Antidepress* or “Monoamine Oxidase Inhibitors” or “Selective Serotonin Reuptake Inhibitors” or “Tricyclic Drugs”
or Acetylcarnitine or Alaproclate or Amersergide or Amiflamine or Amineptine or Amitriptyline or Amoxapine or Befloxatone or
Benactyzine or Brofaromine or Bupropion or Butriptyline or Caroxazone or Chlorpoxiten or Cilosamine or Cimoxatone or Citalo-
pram or Clomipramine or Clorgyline or Clorimipramine or Clovoxamine or Deanol or Demexiptiline or Deprenyl or Desipramine
or Dibenzipin or Diclofensine or Dothiepin or Doxepin or Duloxetine or Escitalopram or Etoperidone or Femoxetine or Fluotracen
or Fluoxetine or Fluparoxan or Fluvoxamine or Idazoxan or Imipramine or Iprindole or Iproniazid or isocarboxazid or Litoxetine or
Lofepramine or Maprotiline or Medifoxamine or Melitracen or Metapramine or Mianserin or Milnacipran or Minaprine or Mirtaza-
pine or Moclobemide or Nefazodone or Nialamide or Nomifensine or Nortriptyline or Noxiptiline or Opipramol or Oxaflozane or
Oxaprotiline or Pargyline or Paroxetine or Phenelzine or Piribedil or Pirlindole or Pivagabine or Prosulpride or Protriptyline or Quin-
upramine or Reboxetine or Rolipram or Sertraline or Setiptiline or SSRI* or Teniloxine or Tetrindole or Thiazesim or Thozalinone or
Tianeptine or Toloxatone or Tomoxetine or Tranylcypromine or Trazodone or Trimipramine or Venlafaxine or Viloxazine or Viqualine
or Zimeldine)
2. The CCDANCTR-References Register was searched using a more sensitive set of free-text terms to identify additional untagged/
uncoded reports of RCTs:
Keyword = Depress* or Dysthymi* or “Adjustment Disorder*” or “Mood Disorder*” or “Affective Disorder*” or “Affective Symptoms”
AND
Free-text = Postpartum or “post partum” or post-partum or Postnatal or “post natal” or post-natal
AND
Free-text = Antidepress* or “Monoamine Oxidase Inhibitors” or “Selective Serotonin Reuptake Inhibitors” or SSRI* or “Tricyclic
Drugs” or Acetylcarnitin* or Alaproclat* or Amersergid* or Amiflamin* or Amineptin* or Amitriptylin* or Amoxapin* or Befloxaton*
or Benactyzin* or Brofaromin* or Bupropion or Butriptylin* or Caroxazon* or Chlorpoxiten or Cilosamin* or Cimoxaton* or Citalo-
pram or Clomipramin* or Clorgylin* or Clorimipramin* or Clovoxamin* or Deanol or Demexiptilin* or Deprenyl or Desipramin*
or Dibenzipin or Diclofensin* or Dothiepin or Doxepin or Duloxetin* or Escitalopram or Etoperidon* or Femoxetin* or Fluotracen
or Fluoxetin* or Fluparoxan or Fluvoxamin* or Idazoxan or Imipramin* or Iprindol* or Iproniazid or isocarboxazid or Litoxetin*
or Lofepramin* or Maprotilin* or Medifoxamin* or Melitracen or Metapramin* or Mianserin or Milnacipran or Minaprin* or Mir-
tazapin* or Moclobemid* or Nefazodon* or Nialamid* or Nomifensin* or Nortriptylin* or Noxiptilin* or Opipramol or Oxaflozan*
or Oxaprotilin* or Pargylin* or Paroxetin* or Phenelzin* or Piribedil or Pirlindol* or Pivagabin* or Prosulprid* or Protriptylin* or
Quinupramin* or Reboxetin* or Rolipram or Sertralin* or Setiptilin* or Teniloxin* or Tetrindol* or Thiazesim or Thozalinon* or
Tianeptin* or Toloxaton* or Tomoxetin* or Tranylcypromin* or Trazodon* or Trimipramin* or Venlafaxin* or Viloxazin* or Viqualin*
or Zimeldin*
3. The Cochrane Central Register of Controlled Trials (CENTRAL) and the specialised register of the Cochrane Pregnancy and
Childbirth Review Group were searched with the following terms: Postnatal or postpartum or puerper*
4. Searches for grey literature included:
• The HSRProj in the National Library of Medicine, Washington D.C was checked for unpublished trials.
• References from MIDIRS Midwifery Database was searched.
• Current Controlled Trials web site: http://www.controlled trials.com/terms2.cfm was examined for ongoing studies.
• The Science Citation Index was checked for references to all included studies.
• Conference proceedings were examined where possible (details available from authors on request).
5. Reference lists
The reference lists of all included studies were checked to identify additional studies missed from the original electronic searches
(for example unpublished or in-press citations). Relevant book chapters and their bibliographies were searched (details available from
authors on request).
6. Correspondence
Pharmaceutical companies were contacted directly for any relevant unpublished data.
Contact was made with authors of identified trials and with experts in the field including a search for non-English material (Professor
L Appleby, Professor P Boyce, Dr T Brugha, Dr L Cohen, Dr N Glangeaud, Dr S Glasser, Dr M Marks, Dr A Wieck, Professor K
Wisner).
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Contact with the Marcé Society through the newsletter was made.
Self help groups were contacted (the National Childbirth Trust (NCT), The Association for Postnatal Illness, Postnatal Distress
Association of Ireland, Postpartum Support International (PSI) and PaNDA).
Appendix 3. Update searches conducted to February 2018
Database: CENTRAL
Host: Wiley
Data Parameters: Issue 1 of 12, January 2018
Date searched: Tuesday, February 13th 2018
Searched by: Chris Cooper
Hits: 18
Search strategy:
ID Search Hits
#1 (postpartum or post partum or postnatal or post natal or puerper*) 9779
#2 MeSH descriptor: [Antidepressive Agents] explode all trees 5750
#3 (antidepress* or anti depress* orMAOI* or RIMA* ormonoamine oxidase inhibit* or ((serotonin or norepinephrine or noradrenaline
or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or “re-uptake”)) or noradrenerg* or
antiadrenergic or anti adrenergic or SSRI* or SNRI* or NARI* or SARI* NDRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*
or psychotropic*) .mp. 1080
#4 (Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Befloxatone
or Benactyzine or Binospirone or Brofaromine or Bupropion or Amfebutamone or Butriptyline or Caroxazone or Cianopramine or
Cilobamine or Cimoxatone or Citalopram or Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine or Clorgyline
or Clovoxamine or CX157 or Tyrima or Demexiptiline or Deprenyl or Desipramine* or Pertofrane or Desvenlafaxine or Dibenzepin or
Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine or DVS-233 or Escitalopram or
Esmirtazapine or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or Hyperforin or Hypericum or “St John*” or
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran or Lofepramine* or “Lu AA21004” or Vor-
tioxetine or “Lu AA24530” or “LY2216684” or Edivoxetine or Maprotiline or Melitracen or Metapramine or Mianserin or Milnacipran
or Minaprine or Mirtazapine or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Norfenfluramine or
Nortriptylin* or Noxiptilin* or Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezine or Pirlindole or
Pivagabine or Pizotyline or Propizepine or Protriptylin* or Quinupramine or Reboxetine or Rolipram or Scopolamine or Selegiline or
Sertraline or Setiptiline or Teciptiline or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromin* or Trazodone or Trimipramine
or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Zalospirone) 22191
#5 #2 or #3 or #4 24723
#6 #1 and #5 252
Notes: CENTRAL only = 18 records in date range 2016-current
File: GS51 CENTRAL18.txt
Databases: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R)
Host: OVID
Data Parameters: 1946 to Present
Date Searched: Tuesday, February 13th 2018
Searched by: Chris
Hits: 28
Search strategy:
Search Strategy:
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# Searches Results
1 exp Antidepressive Agents/ 134025
2 exp Neurotransmitter Uptake Inhibitors/ 133352
3 exp Monoamine Oxidase Inhibitors/ 20964
4 (antidepress* or anti depress* or MAOI* or RIMA* or
monoamine oxidase inhibit* or ((serotonin or norepinephrine
or noradrenaline or nor epinephrine or nor adrenaline or neu-
rotransmitt* or dopamine*) and (uptake or reuptake or “re-
uptake”)) or noradrenerg* or antiadrenergic or anti adrenergic
or SSRI* or SNRI* or NARI* or SARI* NDRI* or TCA* or
tricyclic* or tetracyclic* or heterocyclic* or psychotropic*).mp
228950
5 (Agomelatine or Alaproclate or Amoxapine or Amineptine
or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Be-
floxatone or Benactyzine or Binospirone or Brofaromine or
Bupropion or Amfebutamone or Butriptyline or Caroxazone
or Cianopramine or Cilobamine or Cimoxatone or Citalopram
or Chlorimipramin* or Clomipramin* or Chlomipramin* or
Clomipramine or Clorgyline or Clovoxamine or CX157 or
Tyrima or Demexiptiline or Deprenyl or Desipramine* or
Pertofrane or Desvenlafaxine or Dibenzepin or Diclofensine or
Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Dulox-
etine or Desvenlafaxine or DVS-233 or Escitalopram or Esmir-
tazapine or Etoperidone or Femoxetine or Fluotracen or Flu-
oxetine or Fluvoxamine or Hyperforin or Hypericum or “St
John*” or Imipramin* or Iprindole or Iproniazid* or Ipsapirone
or Isocarboxazid* or Levomilnacipran or Lofepramine* or “Lu
AA21004” or Vortioxetine or “Lu AA24530” or “LY2216684”
or Edivoxetine or Maprotiline or Melitracen or Metapramine
or Mianserin or Milnacipran or Minaprine or Mirtazapine or
Moclobemide orNefazodone orNialamide orNitroxazepine or
Nomifensine or Norfenfluramine or Nortriptylin* or Noxip-
tilin* or Opipramol or Oxaflozane or Paroxetine or Phenelzine
or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or
Pizotyline or Propizepine or Protriptylin* or Quinupramine or
Reboxetine or Rolipram or Scopolamine or Selegiline or Sertra-
line or Setiptiline or Teciptiline or Thozalinone or Tianeptin*
or Toloxatone or Tranylcypromin* or Trazodone or Trim-
ipramine or Venlafaxine or Viloxazine or Vilazodone or Viqua-
line or Zalospirone).ti,ab,kw
76654
6 1 or 2 or 3 or 4 or 5 374868
7 Depression, Postpartum/ 4532
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(Continued)
8 ((postpartum or post partum or postnatal or post natal or puer-
per*) adj3 (depress* or dysthymi* or “adjustment disorder*” or
“mood disorder*” or “affective disorder*” or “affective symp-
tom*”)).ti,ab,kw
5566
9 7 or 8 6988
10 randomized controlled trial.pt. 453387
11 controlled clinical trial.pt. 92150
12 (randomized or randomised).ti,ab. 517074
13 (RCT or “at random” or (random* adj3 (administ* or allocat*
or assign* or class* or control* or determine* or divide* or
division or distribut* or expose* or fashionor number* or place*
or recruit* or subsitut* or treat*))).ti,ab,kw
433913
14 placebo.ab. 186351
15 ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or
dummy)).ti,ab,kw
156034
16 (control* adj3 (trial or study or group*)).ti,ab,kw. 692411
17 (group* adj3 (allocat* or assign* or control* or divide* or divi-
sion or distribut* or treat*)).ti,ab,kw
730860
18 trial.ti,ab. 491130
19 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 1726074
20 6 and 9 and 19 133
21 (2016* or 2017* or 2018*).yr,dt,ed,ep. 3328698
22 20 and 21 28
Notes: N/A
File: GS51MEDLINE28.txt
Database: Embase
Host: OVID
Data Parameters: 1974 to 2018 February 12
Date searched: Tuesday, February 13th 2018
Searched by: Chris Cooper
Hits: 50
Search strategy:
Search Strategy:
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# Searches Results
1 exp Antidepressant Agent/ 401718
2 Neurotransmitter Uptake Inhibitors/ 155
3 exp Monoamine Oxidase Inhibitor/ 45668
4 (antidepress* or anti depress* or MAOI* or RIMA* or
monoamine oxidase inhibit* or ((serotonin or norepinephrine
or noradrenaline or nor epinephrine or nor adrenaline or neu-
rotransmitt* or dopamine*) and (uptake or reuptake or “re-
uptake”)) or noradrenerg* or antiadrenergic or anti adrenergic
or SSRI* or SNRI* or NARI* or SARI* NDRI* or TCA* or
tricyclic* or tetracyclic* or heterocyclic* or psychotropic*).mp
319952
5 Psychopharmacology/ 26480
6 Psychotropic Agent/ 27346
7 Serotonin Receptor Affecting Agent/ or Serotonin Uptake In-
hibitor/ or Serotonin Noradrenalin Reuptake Inhibitor/ or
Triple Reuptake inhibitor/
46515
8 Dopamine Receptor Affecting Agent/ or Dopamine Uptake
Inhibitor/
1482
9 Adrenergic Receptor Affecting Agent/ or Noradrenalin Uptake
Inhibitor/
3576
10 (Agomelatine or Alaproclate or Amoxapine or Amineptine
or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Be-
floxatone or Benactyzine or Binospirone or Brofaromine or
Bupropion or Amfebutamone or Butriptyline or Caroxazone
or Cianopramine or Cilobamine or Cimoxatone or Citalopram
or Chlorimipramin* or Clomipramin* or Chlomipramin* or
Clomipramine or Clorgyline or Clovoxamine or CX157 or
Tyrima or Demexiptiline or Deprenyl or Desipramine* or
Pertofrane or Desvenlafaxine or Dibenzepin or Diclofensine or
Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Dulox-
etine or Desvenlafaxine or DVS-233 or Escitalopram or Esmir-
tazapine or Etoperidone or Femoxetine or Fluotracen or Flu-
oxetine or Fluvoxamine or Hyperforin or Hypericum or “St
John*” or Imipramin* or Iprindole or Iproniazid* or Ipsapirone
or Isocarboxazid* or Levomilnacipran or Lofepramine* or “Lu
AA21004” or Vortioxetine or “Lu AA24530” or “LY2216684”
or Edivoxetine or Maprotiline or Melitracen or Metapramine
or Mianserin or Milnacipran or Minaprine or Mirtazapine or
Moclobemide orNefazodone orNialamide orNitroxazepine or
100164
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(Continued)
Nomifensine or Norfenfluramine or Nortriptylin* or Noxip-
tilin* or Opipramol or Oxaflozane or Paroxetine or Phenelzine
or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or
Pizotyline or Propizepine or Protriptylin* or Quinupramine or
Reboxetine or Rolipram or Scopolamine or Selegiline or Sertra-
line or Setiptiline or Teciptiline or Thozalinone or Tianeptin*
or Toloxatone or Tranylcypromin* or Trazodone or Trim-
ipramine or Venlafaxine or Viloxazine or Vilazodone or Viqua-
line or Zalospirone).ti,ab,kw
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 572354
12 postnatal depression/ 644
13 ((postpartum or post partum or postnatal or post natal or puer-
per*) adj3 (depress* or dysthymi* or “adjustment disorder*” or
“mood disorder*” or “affective disorder*” or “affective symp-
tom*”)).ti,ab,kw
7804
14 12 or 13 8082
15 randomized controlled trial.de. 486416
16 randomization.de. 76792
17 placebo.de. 318178
18 placebo?.ti,ab. 266278
19 (randomized or randomised).ti,ab. 725053
20 double blind procedure/ 146068
21 (RCT or “at random” or (random* adj3 (administ* or allocat*
or assign* or class* or control* or determine* or divide* or
division or distribut* or expose* or fashionor number* or place*
or recruit* or subsitut* or treat*))).ti,ab,kw
586635
22 trial.ti. 241798
23 ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or
dummy)).ti,ab
211307
24 (control* adj3 (trial or study or group*)).ti,ab. 954393
25 (group* adj3 (allocat* or assign* or control* or divide* or divi-
sion or distribut* or treat*)).ti,ab
1039132
26 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 2251280
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(Continued)
27 11 and 14 and 26 260
28 (2016* or 2017* or 2018*).yr,dc. 3762342
29 27 and 28 50
Notes: N/A
File: GS51 Embase50.txt
Database: PscyINFO
Host: OVID
Data Parameters: 1806 to February Week 1 2018
Date searched: Tuesday, February 13th 2018
Searched by: Chris Cooper
Hits: 44
Search strategy:
# Searches Results
1 exp antidepressant drugs/ 36266
2 exp Neurotransmitter Uptake Inhibitors/ 13404
3 monoamine oxidase inhibitors/ 1391
4 (antidepress* or anti depress* or MAOI* or RIMA* or
monoamine oxidase inhibit* or ((serotonin or norepinephrine
or noradrenaline or nor epinephrine or nor adrenaline or neu-
rotransmitt* or dopamine*) and (uptake or reuptake or “re-
uptake”)) or noradrenerg* or antiadrenergic or anti adrenergic
or SSRI* or SNRI* or NARI* or SARI* NDRI* or TCA* or
tricyclic* or tetracyclic* or heterocyclic* or psychotropic*).mp
65272
5 (Agomelatine or Alaproclate or Amoxapine or Amineptine
or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Be-
floxatone or Benactyzine or Binospirone or Brofaromine or
Bupropion or Amfebutamone or Butriptyline or Caroxazone
or Cianopramine or Cilobamine or Cimoxatone or Citalopram
or Chlorimipramin* or Clomipramin* or Chlomipramin* or
Clomipramine or Clorgyline or Clovoxamine or CX157 or
Tyrima or Demexiptiline or Deprenyl or Desipramine* or
Pertofrane or Desvenlafaxine or Dibenzepin or Diclofensine or
Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Dulox-
etine or Desvenlafaxine or DVS-233 or Escitalopram or Esmir-
tazapine or Etoperidone or Femoxetine or Fluotracen or Flu-
oxetine or Fluvoxamine or Hyperforin or Hypericum or “St
John*” or Imipramin* or Iprindole or Iproniazid* or Ipsapirone
or Isocarboxazid* or Levomilnacipran or Lofepramine* or “Lu
32880
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(Continued)
AA21004” or Vortioxetine or “Lu AA24530” or “LY2216684”
or Edivoxetine or Maprotiline or Melitracen or Metapramine
or Mianserin or Milnacipran or Minaprine or Mirtazapine or
Moclobemide orNefazodone orNialamide orNitroxazepine or
Nomifensine or Norfenfluramine or Nortriptylin* or Noxip-
tilin* or Opipramol or Oxaflozane or Paroxetine or Phenelzine
or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or
Pizotyline or Propizepine or Protriptylin* or Quinupramine or
Reboxetine or Rolipram or Scopolamine or Selegiline or Sertra-
line or Setiptiline or Teciptiline or Thozalinone or Tianeptin*
or Toloxatone or Tranylcypromin* or Trazodone or Trim-
ipramine or Venlafaxine or Viloxazine or Vilazodone or Viqua-
line or Zalospirone).ti,ab
6 1 or 2 or 3 or 4 or 5 83585
7 exp Postpartum Depression/ 4151
8 ((postpartum or post partum or postnatal or post natal or puer-
per*) adj3 (depress* or dysthymi* or “adjustment disorder*” or
“mood disorder*” or “affective disorder*” or “affective symp-
tom*”)).ti,ab
4586
9 7 or 8 5597
10 6 and 9 370
11 (2016* or 2017* or 2018*).yr,dc,mo. 377668
12 10 and 11 44
Notes: N/A
File: GS51 PsycINFO44.txt
WH A T ’ S N E W
Last assessed as up-to-date: 13 February 2018.
Date Event Description
13 February 2018 New search has been performed The searches were updated on 13 February 2018
15 September 2016 New citation required but conclusions have not
changed
Review updated
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H I S T O R Y
Protocol first published: Issue 3, 2003
Review first published: Issue 2, 2005
Date Event Description
1 November 2008 Amended Converted to new review format.
31 January 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
This is an update of a previous Cochrane Review. EM and LT undertook the selection of studies, data extraction, quality appraisal and
interpretation of the data. All review authors contributed to the final draft of the review.
D E C L A R A T I O N S O F I N T E R E S T
None.
S O U R C E S O F S U P P O R T
Internal sources
• Health Services Research Dept, Institute of Psychiatry, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Protocol methods were updated from the previous version of this review to reflect current guidance from the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), for example to replace the CCDAN quality rating scale with the Cochrane ’Risk of
bias’ tool. Additional detail was also added to the original methods for clarity.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antidepressive Agents [∗therapeutic use]; Depression, Postpartum [∗prevention & control]; Nortriptyline [therapeutic use]; Random-
ized Controlled Trials as Topic; Sertraline [therapeutic use]
MeSH check words
Female; Humans
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